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ROLE OF COVALENT MODIFICATION OF HYALURONAN WITH INTER-ALPHA 
INHIBITOR HEAVY CHAINS DURING ACUTE LUNG INJURY 
 The extracellular matrix (ECM) provides a structural and signaling platform for 
cells that comprise various organs, playing a critical role in tissue maintenance, injury, 
and repair. Hyaluronan (also known as hyaluronic acid, HA) is a ubiquitous ECM 
polysaccharide consisting of a repeating disaccharide backbone that can be covalently 
modified by the heavy chains (HC) of the serum protein inter-alpha-inhibitor (IαI) during 
inflammation. Known as the only covalent modification of HA, the HC linking of HA is 
exclusively mediated by the inflammation-induced secreted enzyme TNFα-stimulated 
gene-6 (TSG-6). Mice deficient for HC-HA formation, due to the lack of either TSG-6 or 
IαI, display reduced survival during systemic lipopolysaccharide (LPS)-induced 
endotoxic shock and its associated acute lung injury. We therefore hypothesized that 
HC-HA should play an important protective role against acute lung injury induced by 
intratracheal LPS or Pseudomonas aeruginosa (PA) gram-negative bacteria. We also 
identified that lung instillation of LPS or PA caused rapid induction of lung parenchymal 
HC-HA that was largely cleared during resolution of injury, indicative of a high rate of HA 
turnover and remodeling during reversible lung injury. However, using TSG-6 knockout 
mice, we determined that HC-HA exerted minimal protective effects against intratracheal 
LPS or PA-induced acute lung injury. To better address the differential roles of HC-HA 
during systemic versus localized intratracheal exposure to LPS, we characterized and 
compared the induction of HC-HA in plasma and lung in these two models. While lung 
parenchymal HC-HA formed in both injury models, intravascular HC-HA and TSG-6 
were exclusively induced during systemic LPS exposure and were associated with 
improved outcomes, including decreased number of circulating neutrophils and plasma  
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TNFα levels. Our results suggest that LPS induces HC-HA formation in various tissues 
depending on the route of exposure and that the specific intravascular induction of HC-
HA during systemic LPS exposure may have a protective role during endotoxic shock. 
 
Irina Petrache, M.D., Co-Chair 
Carmella Evans-Molina, M.D., Ph.D., Co-Chair 
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Chapter 1. Introduction 
1.1 Hyaluronan 
1.1.1 Extracellular matrix 
The extracellular matrix (ECM) is the meshwork of proteins and polysaccharides 
secreted and maintained by cells. The function of the ECM is not only to provide 
structural support, but also to supply an interface for the intricate cell-to-cell 
communications and interactions that have allowed multicellular organisms to evolve into 
highly advanced vertebrates. An essential component of the ECM is a family of large 
unbranched polysaccharides known as glycosaminoglycans (GAG) consisting of a 
repeating disaccharide sequence [1].  
GAGs are present in most organisms within the kingdom Animalia, and these 
polysaccharides have affected evolution at both the cellular and organismal levels. The 
glycotransferase enzymatic machinery capable of synthesizing GAG polymer chains [1] 
appeared early during the inception of invertebrate animals [1, 2]. These proteins are 
typically transmembrane proteins anchored at the Golgi apparatus, which would append 
GAG chains to proteins headed to the plasma membrane or secreted extracellularly. 
With the evolution of the earliest chordate predecessors of vertebrates, the 
transmembrane protein encoding an enzyme capable of synthesizing hyaluronan (also 
known as hyaluronic acid, HA) is thought to have evolved from a preexisting GAG 
glycotransferase [3]. HA synthase was unique for also encoding the machinery for 
concomitantly extruding HA out of the plasma membrane into the extracellular space as 
HA was being synthesized [4]. With the advent of the earliest vertebrates, a number of 
proteins emerged with Link protein domains that bind HA [3]. The Link domain consists 
of two anti-parallel triple-stranded β-sheets and two α-helices that form a compact fold 
with a hydrophobic core and surface HA-binding groove [5-7]. This structure is present in 
each of the key vertebrate HA-binding proteins including the cartilage proteoglycan 
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aggrecan, lymphatic vessel endothelial HA receptor 1 (LYVE1), scavenger receptor 
stabilin-2, and cell-surface adhesion receptor CD44. With the Link domain’s ability to 
bind HA, the earliest vertebrates were able to utilize HA and co-evolve specialized 
functions with these Link bearing proteins, allowing HA to serve a range of essential 
structural [8], developmental [9, 10], and immunological [11] roles that feature cell-cell 
and cell-ECM interactions [12]. An example of HA acquiring indispensable roles is the 
developmental requirement of hyaluronan synthase 2 (HAS2) in mice, where cell-HA 
interactions facilitate cell migration and cell-fate specification events required for cardiac 
morphogenesis [10].  
1.1.2 HA structure and synthesis 
The GAG family of unbranched polysaccharides consists of alternating sequence 
of a uronic sugar or galactose (glycos) and an amino sugar (aminoglycan) as implied by 
its name [1]. The repeating disaccharide of HA (Figure 1.1A) consists of the uronic 
sugar, D-glucuronic acid (GlcUA), and the amino sugar, N-acetylglucosamine (GlcNAc), 
joined by a β-(1→3) glycosidic link. GlcNAc and the next GlcUA are joined by a β-(1→4) 
glycosidic link [1]. High molecular weight (HMW) HA as large as 10 megaDalton in size 
is found in the synovial fluid with the large HA containing upwards of 30,000 of the 
disaccharide repeats [13, 14]. When mixed with water, HA forms a viscoelastic solution 
occupying enormous hydrodynamic volume. The water uptake has been attributed to the 
amino and carboxylate side groups present on the amino sugar and hexuronic acid, 
respectively, which function together to bind and retain water (Figure 1.1B). Because of 
these unique biochemical properties, HA makes important contributions to essential 
cellular processes that require the ECM, such as cell migration, differentiation, and 
proliferation [15].  
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Figure 1.1. HA structure 
A. As a GAG, HA is a linear (unbranched) polysaccharide chain consisting of a repeating 
disaccharide sequence. The HA disaccharide sequence consists of D-glucuronic acid 
(GlcUA) and N-acetylglucosamine (GlcNAc) joined by a β-(1→3) glycosidic link. The 
glycosidic links alternate between β-(1→3) and β-(1→4) along the chain. Note the 
absence of sulfate modification on the free hydroxyl groups. B. In the presence of water, 
HA forms hydrogen bonds with water through its amide and carboxylate side chains.  
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Besides HA, the other four members of the GAG family of polysaccharides are 
heparin sulfate, chondroitin sulfate, dermatan sulfate, and keratan sulfate. As their 
names suggest, the hydroxyl side groups at different positions on the saccharide units of 
these GAGs can be modified by a sulfate group [1]. Additionally, these GAGs are 
typically covalently linked to a core protein and exist as proteoglycans throughout the 
body. Since the sulfation can vary appreciably between any two chains, these GAGs 
encode tremendous molecular heterogeneity. Further diversity and functionality are 
achieved when multiple GAGs are attached the same core protein. In striking contrast, 
HA is homogenous with the only variable being the size of the polysaccharide, because 
the saccharides of HA are not sulfated and are not linked to any core protein. The 
reason for this has to do with how HA polysaccharide is not synthesized within the 
endoplasmic reticulum and Golgi apparatus like other GAGs, but rather HA is uniquely 
synthesized at the inner plasma membrane and extruded into the extracellular space as 
it is being made [12]. This unique HA property allowed cells to bypass the size 
constraints of synthesizing GAGs within endoplasmic reticulum and Golgi apparatus. 
Consequently, HA is the largest GAG macromolecule in the ECM. Whereas the typical 
size of HMW HA present in uninjured tissue is greater than 1 megaDalton, all other 
GAGs are less than 50 kiloDalton (kDa) [16].  
In mammals, there are three homologous membrane proteins encoding HA 
synthases (HAS1-3) that synthesize and extrude HA at the plasma membrane [17]. The 
disaccharide repeat sequence is generated by sequential transfer of an intracellular pool 
of nucleotide activated GlcUA and GlcNAc to the growing polysaccharide chain. The 
three HAS have different rates of synthesis and generate HA of different size 
distributions with HAS2 generating the largest HA (>2 megaDalton) [18, 19] and HAS3 
generating the smallest HA (100-100 kDa) [18]. Whereas all three HAS are expressed in 
mice during development and postpartum [17, 20], only HAS2 deficiency is 
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embryonically lethal due to defects in cardiac morphogenesis [10]. Additionally, HAS3 
knockout (KO) mice and tissue-specific HAS2 KO mice that bypass the earlier HAS2-KO 
cardiac lethality have defects in other organs [21, 22], which implicate cell-HA 
interactions in a diverse range of developmental processes. In contrast, the 
developmental and physiological roles of HAS1 remain undefined, likely because HAS1 
is the least physiologically active of the three requiring very high intracellular 
concentrations of nucleotide activated GlcNAc for synthesizing HA [19].  
Bacterial glycosyltransferases capable of synthesizing specific GAG have been 
found in various microbes [2]. Bacterial glycosyltransferases are present for all GAGs 
except keratan and they are more likely to have emerged by convergent evolution rather 
than by horizontal genetic transfer of GAG synthases from animals. Typically, bacterial-
synthesized GAG are different from their animal-synthesized counterparts, because they 
do not undergo sulfation and epimerization modifications. However, due to the lack of 
modifications in vertebrate HA, bacterial-synthesized HA is biochemically identical to 
their vertebrate-counterparts and thus non-immunogenic, which likely provided the 
selection pressure in various Pasteurella and Streptococcus strains for synthesizing HA 
capsules to evade the host immune system [23].    
1.1.3 HA renewal 
HA is notable for its continuous synthesis and degradation during homeostasis 
that allows each tissue to achieve its characteristic molecular weight size distribution and 
level of HA. It has been estimated that up to a third of the total HA mass in the human 
body undergoes turnover every day [24]. In the lung, an estimated 5% of interstitial HA is 
turned over each day, which can increase with Escherichia coli (E. coli) bacteremia [25, 
26]. Continuous turnover occurs locally in peripheral tissues and also systemically when 
interstitial HA in peripheral tissues is drained as lymph to lymph nodes and systemic 
circulation, where it is primarily catabolized by the liver, but also taken up in smaller 
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amounts by the kidney and spleen [24]. The clearance of circulating HA is rapid with a 
half-life of only 2.5-5 min [27, 28] and is primarily mediated by liver sinusoidal endothelial 
cells that efficiently endocytose and catabolize HA in lysosomes [29]. In contrast, the 
turnover of HA in peripheral tissues is several magnitudes slower [30] and varies with 
location [31].  
Hyaluronidases 1 and 2 (HYAL1-2) are the key hyaluronidases expressed in 
mammalian somatic tissue [32]. HYAL1-2 encode endoglycosidases that cleave internal 
β-(1→4) glycosidic links between disaccharide repeats. Comparative analyses of HYAL1 
and HYAL2 KO mice implicate both enzymes as critically important for homeostatic HA 
turnover [29]. HYAL2 is a membrane glycosylphosphatidylinositol-linked hyaluronidase 
essential for clearing HMW HA by degrading HMW HA into smaller 20 kDa fragments 
that can be readily endocytosed by liver sinusoidal endothelial cells for lysosomal 
breakdown into monosaccharides [29, 33]. The exact mechanism of HYAL2-mediated 
cleavage has been debated, but likely involves several plasma membrane proteins 
working in concert to degrade HA: CD44 for binding HA [34-36] and a Na+-H+ exchanger 
that acidifies the local environment for optimal HYAL2 activity [33]. With HYAL2 
deficiency, HA is not broken down into the 20 kDa fragments that can be readily 
endocytosed and lysosomally degraded by hepatic sinusoidal endothelium, which 
causes the accumulation of HMW HA in peripheral tissues and especially overloads the 
lymph nodes and systemic circulation that drain the HA in peripheral tissue [29, 33]. In 
utero, this abnormal accumulation of oversized HA leads to craniofacial and heart 
developmental defects in both HYAL2 KO mice and humans [37-39], which implicates 
proper HA input in these morphogenetic processes [10].  
In contrast, HYAL1 is a secreted and endocytosed hyaluronidase that has 
optimal activity in acidic lysosomes when the pH is 3.8 [40, 41]. HYAL1 deficiency leads 
to a lysosomal storage disorder [42] characterized by significant HA accumulation in the 
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liver sinusoids and minor increases in peripheral tissue, lymph nodes, and plasma [29]. 
In both mice and humans, the typical presentation of HYAL1 deficiency is joint 
inflammation due to abnormal joint macrophages and fibroblasts that have lysosomes 
overloaded with HA [43, 44]. With the relative absence of developmental defects in both 
mice and humans and less HA accumulation outside the liver as compared to HYAL2 
deficiency [42, 43, 45], it has been suggested that HYAL1 deficiency can be partially 
compensated for by lysosomal exoglycosidases β-hexosaminidase and β-glucuronidase, 
which catabolize HA by removing terminal saccharides instead of targeting the internal 
glycoside links, as in the case of HYAL1-2 [46].  
It was recently discovered that there are two related proteins in humans that can 
degrade HMW HA: transmembrane protein 2 (TMEM2) and cell migration-inducing and 
HA binding protein (CEMIP, also known as KIAA1199), which feature domains 
homologous to bacterial polysaccharide lyases, but have no homology to HYAL1-2 and 
other hyaluronidase-like genes, can promote HA breakdown [47]. While TMEM2 is a 
membrane protein that can directly cleave extracellular HMW HA [47], CEMIP is a 
secreted HA-binding protein that promotes HA-binding and endocytosis [48, 49]. During 
development, TMEM2-mediated HA degradation has been implicated in angiogenesis in 
zebrafish [50], and mutations in the CEMIP gene that impair the ability of its encoded 
product to endocytose and clear HA lead to hearing defects in humans [48]. The role of 
these two proteins in HA turnover in adult tissues is unclear, but CEMIP may play a role 
in homeostatic HA turnover in human skin fibroblasts [48]. Another protein implicated in 
HA-binding and endocytosis is the scavenger receptor stabilin-2 (also known as HA 
receptor for endocytosis, HARE) [51]. Highly expressed in liver sinusoidal endothelial 
cells for systemic HA clearance by endocytosis, Stabilin-2 KO mice exhibited an 
increased accumulation of HA in plasma [52].   
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1.2 Heavy-chain modified hyaluronan 
1.2.1 Structure 
The repeating dissacharide backbone of HA is unique for its ability to be modified 
with a polypeptide. While the other glycosaminoglycans are attached to proteoglycan 
core proteins via a saccharide linker, their disaccharide backbone cannot be modified by 
peptide and instead obtain their unique functionality through sulfation. The modification 
of HA with the heavy-chains (HC) of the serum protein inter-alpha-inhibitor (IαI) is the 
only known covalent modification of HA (Figure 1.2A). The discovery of the addition of 
the HC polypeptide to HA was first made when HA isolated from the synovial fluid of 
inflamed joints was found to be complexed with protein matching serum IαI, which was 
noticeably absent in healthy joints [53]. This specific presentation of HC-modified HA 
(HC-HA) in tissue during inflammation coincides with two events typically associated 
with inflammation and both of these events are critical for the catalysis of this HC-HA 
covalent modification. The first event required for forming the HC-HA modification is the 
induction of the tumor necrosis factor α (TNFα) stimulated gene-6 (TSG-6) enzyme 
responsible for catalyzing the modification (Figure 1.2B). The second required event is 
the inflammation-induced vascular leak of the serum IαI that serves as the enzymatic 
substrate.  
TSG-6 catalyzes the covalent modification via two transesterification reactions 
(Figure 1.2C). During the first reaction, TSG-6 removes a HC from the serum protein 
inter-alpha-inhibitor (IαI) to form a TSG-6-HC intermediate. In the presence of HA, TSG-
6 then transfers the HC to HA to form HC-modified HA and TSG-6 is regenerated and 
available to catalyze another covalent modification [54]. This covalent modification 
specifically occurs at the C6 hydroxyl group of the GlcNAc saccharide of HA [55]. 
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Figure 1.2. TSG-6 transesterification reactions 
A-B. HA is a linear polysaccharide with a repeating disaccharide sequence: GlcUA 
(green) and GlcNAc (orange). HA can be covalently modified with the heavy-chains (HC; 
blue ovals) of inter-alpha-inhibitor (IαI). The covalent modification is exclusively mediated 
by the enzyme TNFα stimulated gene-6 (TSG-6). TSG-6 is a secreted protein consisting 
of HA-binding Link and CUB domains. IαI contains a chondroitin sulfate polysaccharide 
chain that is covalently linked with a HC1, HC2, and light chain protein known as bikunin. 
Cartoon by Ni et al. [56], open source.  C. Schematic representation of the two 
transesterification reactions mediated by TSG-6 enzyme, adapted from [54]. A 
conserved serine residue on TSG-6 is responsible for carrying out the two reactions. In 
the first reaction, the TSG-6 serine removes a HC from IαI by forming an ester bond with 
the terminal aspartate of HC. In the second reaction, the TSG-6-HC intermediate 
modifies the C6 hydroxyl of a GlcNAc present in HA with HC and regenerates TSG-6, so 
that it can catalyze another modification. Besides TSG-6 enzyme and IαI substrate, the 
two transesterifications only require the presence of divalent metal cations (Mg2+ and 
Ca2+) [57-59]. The energy for the reaction is stored in IαI at the HC-chondroitin sulfate 
bond [57].        
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IαI is a serum protein consisting of two HC (HC1 and HC2) proteins and a light 
chain protein known as bikunin attached to the same chondroitin sulfate polysaccharide 
chain [60]. Like most serum proteins, IαI is assembled inside hepatocytes and secreted 
by the liver. IαI was initially recognized as a protease inhibitor due to bikunin being a 
Kunitz-type serine protease inhibitor. However, interest has turned to the 
characterization of HC-ECM interactions and the systemic role of the two HCs, because 
bikunin’s physiologic role as a protease inhibitor role is likely relatively minor [61]. HCs 
contain one von Willebrand type A (vWA) domain, also seen in many other ECM 
proteins [60, 62], that allow it to bind various other ECM components like vitronectin [63]. 
The finding that HC regulates complement [64, 65] and neutrophil [66] activation 
suggests that HC has important roles during systemic inflammation. In this context, HC-
HA may provide a scaffold that binds inflammatory cells expressing the HA receptor 
CD44 and promotes their undergoing HC-mediated effects.       
1.2.2 TNFα Stimulated Gene-6 
TSG-6 was first discovered in TNFα-treated foreskin fibroblasts [67] as an 
inflammation-induced secreted protein. The proinflammatory cytokines TNFα and 
interleukin 1β (IL1β) were soon identified as the key inflammatory stimuli for TSG-6 gene 
transcription in non-hematopoietic cells [68]. Both cytokines promote transcriptional 
factor binding at essential NF-IL6 binding sites and a secondary AP-1 site in the TSG-6 
promoter, which collectively serve to enhance TSG-6 transcriptional expression [69, 70]. 
The TSG-6 protein consists of a HA-binding Link domain and a complement Clr/Cls, 
uegf urchin epidermal growth factor, and bone morphogenetic protein 1 (CUB) domain. 
Like other proteins bearing a Link domain for binding HA, TSG-6 appeared in the earliest 
vertebrate ancestor [3]. TSG-6 features a serine residue, which is adjacent to the Link 
domain, that is responsible for removing HC from IαI. The importance of the association 
of HC with TSG-6 is emphasized by the finding that the catalytic TSG-6 serine is 
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evolutionarily conserved in all vertebrates from fish to mammals (Figure 1.3) [71, 72]. 
The Link domain in TSG-6 has an extremely high affinity for HA, much higher than the 
Link domain in the cell-surface adhesion receptor CD44 [73], which may allow TSG-6 to 
effectively bind HA and repeatedly modify it during inflammation [74].  
Like the Link domain, the CUB domain of TSG-6 is also well conserved and 
essential for HC-HA formation [75]. Specifically, the TSG-6 CUB domain promotes the 
Ca2+-dependent non-covalent interaction of TSG-6 with the Mg2+-binding vWA domains 
present on IαI’s HCs. This TSG-6 engagement with the vWA domain, which is the first 
step in forming the TSG-6-HC covalent intermediate [58], is the likely reason for the 
TSG-6 enzymatic requirement for the divalent metals Mg2+ and Ca2+. It has also been 
proposed that the CUB domain may facilitate dimerization of HA-bound TSG-6, which 
has implications on how TSG-6-binding of HA can potentially reorganize HA 
ultrastructure [75].  
The evolutionarily conserved role of TSG-6 in covalently modifying HA was 
established in mice with the discovery that oocyte release from the ovary required its 
surrounding HA-rich matrix to be covalently modified with HC. Both TSG-6 and IαI 
deficiency led to identical phenotypes of complete infertility due to lack of HC-HA in the 
cumulus ECM surrounding the oocyte [76, 77]. Lack of pentraxin-related protein 3 
(PTX3, also known as TSG-14), which is localized non-covalently to the HC-HA-enriched 
cumulus matrix and binds TSG-6, was found to only cause subfertility [78, 79].  These 
findings show that HC-HA modification can orchestrate large-scale reorganization of 
ECM to perform specific functions. 
It was recently reported in chickens and mice that HC-HA plays a key 
developmental role in vertebrate midgut rotation and intestinal left-right asymmetry that 
was similarly impaired in TSG-6 KO mice and IαI KO mice [80]. Since cumulus cell-
directed oocyte release is limited to mammals [81], this discovery was very important in 
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that it established a developmental role of HC-HA that is likely evolutionarily conserved 
across all vertebrates. Specifically, HC-modification of HA potentiated a HA-enriched 
ECM expansion that was critical for initiating midgut rotation and inhibiting vascular 
development in the right dorsal mesentery [80]. While it was suggested that TSG-6 KO 
embryos may exhibit reduced viability due to midgut malrotation, which can give rise to 
life-threatening intestinal strangulation, we have not observed any non-Mendelian 
inheritance trends among our pups from heterozygote (HT) x KO and HT x HT breeding 
schemes that would suggest reduced viability in TSG-6 KO mice (Table 1-1). 
Additionally, two other research groups have independently confirmed that IαI breeding 
schemes lead to Mendelian inheritance trends, which argues against any viability deficits 
due to HC-HA deficiency [76, 82]. These observations were consistent with how we have 
not observed any deficits from pup to adulthood and the clinical observation that most 
cases of intestinal malrotation do not lead to life-threatening volvulus and strangulation 
[83, 84].   
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Figure 1.3. Conservation of TSG-6 serine residue that catalyzes HC-HA formation 
Sequence alignment of TSG-6 pro-protein in vertebrates (residues 1-47 shown, 
numbering based on human TSG-6) containing the signal peptide (highlighted in brown) 
and first few residues of the HA-binding Link domain (highlighted in green). The serine 
residue responsible for removing HC from IαI (highlighted in yellow) is evolutionarily 
conserved across all vertebrates from fish to mammals. Species analyzed: Homo 
sapiens (human), Mus musculus (mouse), Equus caballus (horse), Bos taurus (cattle), 
Pelodiscus sinensis (chinese softshell turtle), and Danio rerio (zebrafish). CLUSTAL 
multiple sequence alignment was completed using MUSCLE 3.8 (MUltiple Sequence 
Comparison by Log-Expectation); “*” (asterisk) denotes fully conserved residue. “:” 
(colon) denotes residues with strongly similar properties (>0.5 in Gonnet PAM 250); “.” 
(period) denotes residues with weakly similar properties (≤0.5 in Gonnet PAM 250). 
Alignment from Ni et al. [56], open source. 
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HT (female) x HT (male) viable pups 
     
  WT HT KO Total 
Female 40 56 33 129 
Male 24 45 28 97 
Observed Total 64 101 61 226 
Expected Total 32.25 64.5 32.25 129 
Observed % 28.3185841 44.69027 26.99115   
Expected % 25 50 25   
     
     
HT (female) x KO (male) viable pups  
     
  HT KO Total  
Female 85 71 156  
Male 55 67 122  
Observed Total 140 138 278  
Expected Total 139 139 278  
Observed % 50.3597122 49.64029    
Expected % 50.00 50.00    
 
Table 1-1. Offspring of TSG-6 breeding pairs 
Genotypes of mice pups from our two TSG-6 mating pairs: HT (female) x HT (male) and 
HT (female) x KO (male). Expected total counts were calculated using Mendelian 
inheritance ratios of 1:2:1 (WT:HT:KO) and 1:1 (HT:KO) for HT x HT and HT x KO 
breeding schemes. WT, wildtype. HT, heterozygote. KO, knockout.  
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1.3 Acute lung injury and endotoxic shock 
1.3.1 Acute respiratory distress syndrome and acute lung injury 
Acute lung injury (ALI) and its corresponding clinically defined condition acute 
respiratory distress syndrome (ARDS) are the leading causes of morbidity and mortality 
in the critical care setting. ARDS describes an acute, non-cardiogenic condition in the 
lungs where alveolar endothelial and epithelial barriers become permeable and allow the 
vascular leak of protein, fluid, and leukocytes into the lung, which severely impair gas 
exchange. Underlying infections, either systemic (sepsis) or local (pneumonia), are the 
leading causes of ARDS and carry an increased mortality risk compared to ARDS 
triggered by non-infectious causes [85-87]. Although recent advances in ARDS have 
been achieved with lung protective approaches to mechanical ventilation, after thirty 
years of clinical trials, no therapeutic breakthroughs in pharmacological interventions 
have been developed, likely due to the heterogeneity of ARDS [88].     
1.3.2 Sepsis and endotoxic shock  
Sepsis is defined clinically as an infection, typically bacterial, that causes 
systemic inflammatory response, which is characterized by life-threatening 
microvascular inflammation and permeability that can cause multiple organ dysfunction, 
including ARDS in the lungs. Pneumonia is the leading cause of sepsis, accounting for 
40-60% of cases, followed by intra-abdominal and urinary tract infections [89]. This 
significant overlap of pneumonia, sepsis, and ARDS highlights the common 
pathophysiological disruption of the alveolar microvascular endothelial and epithelial 
barrier function that is driven by lung and systemic inflammatory cross-talk.  
Endotoxic shock from endotoxemia refers to severe systemic inflammatory 
response that follows exposure to circulating endotoxin, a component of the bacterial 
outer membrane. The prototypical endotoxin is lipopolysaccharide (LPS), a hallmark 
gram negative bacterial pathogen-associated molecular pattern (PAMP) used to 
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experimentally study the innate immune response to gram negative bacteria. Endotoxic 
shock is often used interchangeably with septic shock, but septic shock specifically 
refers to severe systemic inflammatory response with persistent hypotension that is 
generated in response to circulating microbial organisms in the bloodstream.  
Like ARDS, clinical trials for sepsis have not yielded any breakthroughs in 
targeted pharmacological interventions [90]. Since Toll-like receptor 4 (TLR4) and 
inflammatory cytokines TNFα and IL1β have been implicated in endothelial 
microvasculature instability, therapies were developed to block the effects of these 
proteins during sepsis. While showing promise in animal studies, none of these 
therapies were found to be effective in phase III clinical trials [91-93]. Therefore, 
treatment of sepsis remains primarily supportive including antibiotics for bacterial 
infection and conservative fluid resuscitation for septic shock. 
1.3.3 Mice models of ALI and endotoxic shock 
ALI can be modeled in mice by direct delivery via trachea (intracheal instillation, 
IT) of live bacteria or LPS extracted from gram negative bacteria. A single IT instillation 
of bacteria or LPS elicits a neutrophilic inflammatory response in the lung and disrupts 
the alveolar microvascular barrier [94]. The rapid neutrophil recruitment that follows IT 
instillation of live gram negative bacteria including Pseudomonas aeruginosa (PA) is 
essential for controlling bacterial proliferation in the respiratory tract [95-97]. The initial 
neutrophilic response is followed by recruitment of macrophages and lymphocytes that 
promote clearance of apoptotic neutrophils and resolution of inflammation [98, 99]. 
Either IT LPS- or PA- induced ALI in mice resolves without the late fibroproliferative 
responses of ARDS that may be a consequence of continuous airway epithelial insult by 
mechanical ventilation, combined with maladaptive host responses [100, 101].  
Intraperitoneal (IP) administration of a high LPS dose in mice induces life-
threatening endotoxic shock and ALI driven by lung microvascular permeability [94]. 
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Both the IP LPS-induced endotoxic shock model and the cecal ligation and puncture 
(gram negative peritoneal and systemic infection) model cause neutrophilic 
accumulation in lung microvasculature and interstitium, but the neutrophil recruitment to 
the intra-alveolar spaces is minimal due to the maintenance of a largely intact alveolar 
epithelial barrier. The innate immune response to sequester neutrophils in the lung 
microvasculature following systemic LPS or bacteremia in mice contributes to acute lung 
respiratory failure similar to that seen with ARDS septic patients. While these 
sequestered neutrophils clear circulating gram negative bacteria [102, 103], a 
disproportionate neutrophil response in the lung during sepsis may cause more harm 
than benefit. Experimentally, lung sequestration diverts neutrophils from other organs, 
which was found in mice to be detrimental when bacterial infection was seeded 
intraperitoneally [104]. During the hyperactive innate immune response of endotoxic 
shock and sepsis, neutrophil trafficking and effector responses may be impaired and 
contribute to excessive vascular instability and tissue injury. Therefore, understanding 
how the ECM regulates neutrophil activation and directs their trafficking during 
experimental models of endotoxic shock and sepsis may yield new therapeutic targets.      
1.4 Role of HA during inflammation 
1.4.1 HA fragmentation 
Inflammation is characterized by enhanced degradation and turnover of tissue 
HA. The relative contributions of hyaluronidases and reactive oxygen species (ROS) in 
HA breakdown remain unclear, but both likely contribute during inflammation [16]. It has 
been hypothesized that the low molecular weight (LMW) HA fragments generated during 
inflammation may act as damage-associated molecular pattern molecules (DAMPs) 
stimulating pro-inflammatory responses in the injured tissue. On the other hand, the 
generation of HA fragments may be important for proper clearance and resolution of 
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inflammation. For example, IT hyaluronidase administration after influenza A-induced 
respiratory infection in mice accelerated recovery [105].     
A caveat of the pro-inflammatory effects of LMW HA reported in many studies is 
the potential endotoxin contamination. A recent study showed that non-pharmaceutical 
grade HA and hyaluronidase reagents contained significant endotoxin contamination that 
cannot be effectively removed by polymyxin B treatment [106]. Additionally, the study 
reported that endotoxin-free pharmaceutical grade HA did not have any inflammatory 
effects on bone marrow-derived macrophages and dendritic cells. Therefore, one should 
be cautious when interpreting results obtained with exogenous HA or hyaluronidase 
treatments.  
1.4.2 HA in inflammatory trafficking 
Interactions between HA and its CD44 receptor have been implicated in 
hematopoietic cell trafficking during inflammation. CD44 antibody blockade can interfere 
with monocyte [107] and macrophage [108] recruitment. Neutrophil adhesion in the liver 
sinusoids after either IP LPS or gram negative E. coli administration is similarly 
abolished with CD44 antibody blockade [109], which places HA at the center of the 
hepatic inflammatory response to gram negative bacterial sepsis. This neutrophil 
sequestration in the liver sinusoids can serve a protective role in trapping and removing 
circulating bacteria [102]. Macrophage efferocytosis of damaged or apoptotic neutrophils 
can induce reprogramming that suppresses production of proinflammatory cytokines 
[110, 111]. Since neutrophil activation and destruction of circulating bacteria can also 
lead to damage to underlying endothelial cells, such as hepatotoxicity in the liver and ALI 
in the lung, careful modulation of neutrophil sequestration and trafficking is needed to 
counter sepsis-induced mortality.    
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1.4.3 HA in bone marrow 
Mortality from sepsis is greatest among elderly and infants, and post-mortem 
findings frequently uncover unresolved infectious foci suggestive of immunosuppression 
or immunological derangements [112, 113]. Experimental sepsis can cause 
hematopoietic stem and progenitor cell exhaustion and myelosuppression that presents 
as life-threatening neutropenia and inability to control bacterial infection [114, 115]. 
Neutropenia due to leukemia or other hematologic malignancies is a leading risk factor 
for sepsis [116]. The role of HA and HC-HA in the bone marrow remains largely 
undefined, but there is increasing evidence that they may be critical during systemic 
conditions that stress and mobilize the bone marrow compartment such as sepsis. A 
recent mouse study demonstrated the role of CD44-HA interactions in enhancing 
hematopoietic progenitor cell proliferation and improving progenitor engraftment after 
irradiation [117]. Our lab has previously shown that exogenous TSG-6 supplementation 
in mice improves hematopoietic progenitor cell function after cigarette smoke-induced 
myelosuppression [118]. Other labs have shown that TSG-6 KO mice or exogenous 
TSG-6 supplementation can alter bone marrow stromal cell differentiation [119-121]. 
These studies underscore the possibility that HC-HA may act in the bone marrow during 
sepsis.    
1.4.4 HC-HA in chronic lung diseases 
Chronic lung inflammation is characterized by tissue remodeling processes that 
promote aberrant extracellular collagen synthesis and deposition that lead to the 
generation of pathological lesions. A hallmark of many chronic lung diseases such as 
pulmonary arterial hypertension [122], asthma [123], cystic fibrosis [124], and idiopathic 
pulmonary fibrosis [125] is the accumulation of HC-HA in these histopathological lesions. 
The accumulation of HC-HA in the lung has been suggested to have a pro-inflammatory 
role. The strongest evidence for pro-inflammatory HC-HA is from mouse models of 
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reactive airway disease. Specifically, mice lacking the ability to form HC-HA, either TSG-
6 or IαI KO, were found to exhibit decreased airway hyperresponsiveness after 
ovalbumin [126] or ozone injury [127, 128].  
However, with other chronic lung diseases, it remains unclear whether the 
presence of HC-HA directly contributes to inflammation, as association does not imply 
causation. During chronic lung inflammation, HA deposits can co-localize with collagen 
deposits in the peri-broncho-vascular interstitium [129]. Adhesion and contact with HA is 
thought to regulate fibroblast and myofibroblast programming [130], which is especially 
important during bleomycin-induced lung fibrosis [131, 132]. The role of HC-HA during 
bleomycin-induced fibrotic reprogramming remains unclear. While HC-HA deficiency (IαI 
KO mice) did not alter key bleomycin-induced fibrosis and collagen deposition outcomes, 
differences in neovascularization and bronchoalveolar lavage inflammatory cell counts 
were noted [125].  
It is important to acknowledge that HC-HA may also have protective effects in the 
lung. In particular, mice lacking the ability to form HC-HA, IαI-KO, exhibited impaired 
bronchial epithelial repair responses [63]. These diverse findings highlight how HC-HA 
may have complex roles during lung injury and repair and underscore the need for 
additional mechanistic studies.  
1.4.5 HC-HA in endotoxic shock 
Although HA can be found in the lung microvasculature, its levels are much 
higher, by 500-600 fold, in the liver sinusoid vasculature, which contains the highest 
systemic concentration of HA due to its role as the filter for circulating HA [133]. During 
endotoxic shock, liver sinusoidal HA is extensively covalently modified with HCs from IαI 
[134]. This formation of HC-HA was found to promote neutrophil adhesion in the liver 
sinusoids during endotoxic shock. Mice that lack HC-HA, such as TSG-6 [135] or IαI 
[136] KO mice, exhibited more rapid onset of mortality during IP LPS-induced endotoxic 
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shock. The precise role of trapping neutrophils in liver during bacteremia is not known, 
but may play a protective role in clearing bacteria [102]. Experimentally, neutrophils can 
work in concert with Kupffer cells, which are specialized macrophages lining the walls of 
liver sinusoids, to eliminate systemic bacterial infections [137]. Additionally, Kupffer cells 
have been implicated as part of the mononuclear phagocyte system responsible for 
clearing circulating neutrophils [107]. This clearance of apoptotic neutrophils during 
sepsis may have a protective role in limiting excessive neutrophil-mediated endothelial 
injury.   
Taken together, these findings highlight a key role of HC-HA during endotoxic 
shock. However, the exact mechanisms of HC-HA’s protective effects remain unclear. 
Moreover, the role of HC-HA on injury severity and alveolar barrier repair during ALI 
caused by localized exposure to LPS (via IT) remains unexplored. To address these 
knowledge gaps, we first sought to determine the potential sources of TSG-6 enzyme 
that would catalyze HC-HA formation during ALI and endotoxic shock (Chapter 2). We 
then characterized the kinetics of HC-HA formation during IT LPS and PA-induced ALI 
and examined the role of HC-HA during these models of localized ALI using TSG-6 KO 
mice (Chapter 3). Lastly, we characterized the differential HC-HA formation in the 
systemic vs. lung compartments between IP and IT LPS models and, in this context, we 
examined the role of HC-HA during IP LPS-induced endotoxic shock using TSG-6 KO 
mice (Chapter 4).  
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Chapter 2. Sources of TSG-6 during ALI and endotoxic shock 
2.1 Introduction 
To obtain a spatiotemporal understanding of HC-HA production during LPS-
induced acute inflammation, we focused on identifying the potential cellular sources of 
TSG-6 that would catalyze HC-HA formation in the lung and vasculature. As an 
inflammation-induced secreted enzyme, TSG-6 was originally identified as a protein 
secreted by TNFα-stimulated foreskin fibroblasts [67] and prolifically secreted by 
mesoderm-derived stromal cells including mesenchymal stem cells (MSC) [138] and 
adipose stem and progenitor cell (ASC) [118]. While the lung contains a multitude of 
mesoderm-derived stromal cells in the interstitium including lung fibroblasts and smooth 
muscle cells [139], the respiratory tract and alveoli are lined by endoderm-derived 
epithelial cells and myeloid-derived alveolar macrophages (AM). Additionally, the 
vasculature is lined with non-stromal endothelial cells and circulating throughout the 
blood are hematopoietic cells that can be divided into myeloid and lymphoid lineages.  
Despite advances regarding the potential cellular sources of TSG-6 in the body, 
many questions still remain regarding the relative secretory contributions of inflammatory 
and stromal cells, especially in the context of lung and vasculature during ALI and 
endotoxic shock. In the lung, the documentation of TSG-6 expression and secretion from 
stromal and airway epithelial cells has been limited to gene expression studies [140]. 
While peripheral blood monocytes and peripheral blood monocyte-derived cells have 
been shown to express and secrete TSG-6 [68, 140], we could not find any published 
data whether terminally differentiated alveolar macrophages exhibited this function. Also, 
in the vasculature, while TSG-6 secretion from circulating myeloid cells including 
neutrophils and monocytes are likely contributors to circulating TSG-6 [68, 140], the role 
of endothelial cells as a source of circulating TSG-6 is limited to gene expression data 
from human umbilical vein endothelial cells [140]. These gaps in knowledge highlight a 
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strikingly incomplete understanding of the physiological lung and vascular sources of 
TSG-6 during health and disease.      
It has been established that non-hematopoietic cells, especially stromal cells, can 
respond to the inflammatory cytokines TNFα and IL1β by secreting TSG-6 [68]. In 
contrast, hematopoietic cells of myeloid lineage have been found to secrete TSG-6 in 
response to either TNFα or LPS with the latter being the more powerful inducer [68]. In 
vascular cells, IL1β was identified as a potent stimuli of TSG-6 transcriptional expression 
in human umbilical vein endothelial cells [140].  
With this scientific premise, we addressed the secretory capabilities of potential 
cellular sources of TSG-6 in the lung and vasculature. Focusing on the inflammatory 
signals present during ALI and endotoxic shock, we treated various types of cells with 
LPS, TNFα, and/or IL1β and quantitatively assessed their ability to secrete TSG-6 by 
enzyme-linked immunosorbent assay (ELISA). We additionally analyzed TSG-6 
secretion into conditioned media by western blot and extracted RNA to measure TSG-6 
gene expression.  
2.2 Methods 
2.2.1 Reagents 
All materials and reagents described in Chapters 2-4 were from ThermoFisher 
(Waltham, MA, USA), unless otherwise specified. Cell culture reagents were from Gibco 
(ThermoFisher), unless otherwise specified. 
2.2.2 Cell culture 
Primary human alveolar macrophages (hAM) were obtained by bronchoalveolar 
lavage of de-identified non-diseased human explanted lungs not used for transplantation 
and allowed to attach to tissue culture treated plastic in Roswell Park Memorial Institute 
(RPMI) media with 1X penicillin/streptomycin (100X at 10,000 U/mL) for 2 h. 
Bronchoalveolar lavage was performed by the donor lung tissue core at National Jewish 
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Health following Institutional Review Board (IRB) approved protocol. Non-adherent cells 
were collected and discarded by phosphate buffered saline (PBS) wash. Indicated 
treatments were performed in RPMI media with 2% fetal bovine serum (FBS, HyClone, 
GE Healthcare, Marlborough, MA, USA) and 1X penicillin-streptomycin. Treatments 
included adding 20 ng/mL TNFα (R&D Systems, Minneapolis, MN, USA), 50 ng/mL 
ultrapure E. coli K12 LPS (LPS-EK, InvivoGen, San Diego, CA, USA), or vehicle (0.1% 
bovine serum albumin in PBS) for either 6 h or 24 h. After the collection of conditioned 
media supernatant (1000 g, 10 min) mixed with protease inhibitors (complete Protease 
Inhibitor Cocktail, Roche Diagnostics, Mannheim, Germany), cells were rinsed once with 
PBS and then lysed for RNA extraction per below. 
Peripheral blood monocyte cell (PBMC)-derived macrophages (PBDM) were 
enriched from whole blood by negative selection (DynaBeads untouched human 
monocyte kit) and by adherence to tissue culture plastic. Incubation with macrophage 
colony stimulating factor (20 ng/mL MCSF, R&D Systems) over six days was used to 
differentiate PBMC into macrophage-like cells. Macrophage differentiation was achieved 
in serum-free RPMI supplemented with 1X non-essential amino acids, 1 mM sodium 
pyruvate, 2 mM glutamine, and 1X penicillin-streptomycin for days 1-3 and with 
additional 10% FBS for days 4-6. Treatments were performed in RPMI media with 2% 
FBS and indicated stimuli for 24 h.  
BEAS-2B immortalized human bronchial epithelial cells were cultured in 
submerged conditions using Dulbecco's Modified Eagle Medium (DMEM), high glucose 
(4500 mg/L) media with 10% FBS, and 1X penicillin/streptomycin. Treatments were 
performed by rinsing once with PBS and then incubating in basal DMEM media with 2% 
FBS and indicated stimuli for 24 h.  
Wi38 primary human fetal lung fibroblasts were grown in Minimum Essential 
Media (MEM) media with 10% FBS and 1X penicillin/streptomycin. Cells were used 
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between passages 8-12 for experiments. Treatments were performed by rinsing once 
with PBS and then incubating in basal MEM media with 2% FBS and indicated stimuli for 
24 h. 
Human adipose stromal/progenitor cells (ASC) isolation, expansion, and 
characterization were previously described [118, 141, 142]. All ASC isolation was 
performed by Dr. Keith March’s lab at Indiana University School of Medicine following 
IRB approved protocol. Briefly, ASC were collected by liposuction of three human donors 
(two abdominal and one flank lipoaspirate). ASC isolation involved digestion using 
collagenase I (Worthington, Lakewood, NJ, USA) under mechanical agitation (2 h, 
37 °C) and centrifugation (300 g, 8 min) to obtain a pellet containing the stromal vascular 
fraction. The stromal vascular fraction was filtered (250 μm Nitex filters, Sefar America, 
Buffalo, NY, USA), and red blood cells were lysed using ammonium chloride potassium 
(ACK) lysis buffer (154 mM NH4Cl, 10 mM KHCO3, and 0.1 mM 
ethylenediaminetetraacetic acid or EDTA). The stromal cells were cultured on tissue 
culture plastic using microvascular endothelial cell growth medium (EGM-2-MV) media 
(Lonza, Allendale, NJ, USA), and ASC between passages 4-6 were used for 
experiments. Treatments involved rinsing once with PBS to remove residual FBS and 
incubating in basal Endothelial Basal Medium-2 (EBM-2) media (Lonza) with indicated 
stimuli for 24 h. Demographic information of the ASC donors was described previously 
[143].  
Primary human lung microvascular endothelial cells (HMVEC-L) from Lonza were 
cultured in microvascular endothelial growth medium (EGM-2-MV) following 
manufacturer’s instructions. HMVEC-L were cultured and seeded between passages 6-
7. Treatments involved rinsing once with PBS and incubating for 24 h in EGM-2-MV with 
the following: vehicle containing 0.1% bovine serum albumin (BSA, MilliporeSigma, 
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Burlington, MA, USA) in PBS, 20 ng/mL TNFα (R&D Systems), 20 ng/mL IL1β (R&D 
Systems), or 20 ng/mL ultrapure E. coli K12 LPS (LPS-EK, InvivoGen).  
2.2.3 Human TSG-6 (hTSG-6) western blot  
Conditioned media supernatant (1000 g, 5 min) was mixed with Laemmli buffer. 
Proteins were separated by their molecular weight by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) on Stain-Free Criterion TGX 4-20% 
gradient gels (Biorad, Hercules, CA, USA) and transferred to Immobilon-P PVDF 
membrane (MilliporeSigma) using TransBlot Semi-Dry (Biorad). All blot processing steps 
were performed with rocking and at room temperature unless otherwise specified. The 
blot was blocked in Tris-buffered saline (TBS) with 5% milk dissolved and 0.1% TWEEN-
20 (MilliporeSigma) and probed using goat-anti-hTSG-6 antibody (AF2104, R&D 
Systems) in PBS buffer with 4% BSA (overnight, 4 °C). TBS with 0.1% TWEEN-20 (4 x 
10 min) was used to wash the blots. Bovine anti-goat IgG-HRP (sc-2350, Santa Cruz 
Biotechnology, Dallas, TX, USA) secondary was used at 1:5000 in TBS with 5% milk 
and 0.1% TWEEN-20. Chemiluminescent horseradish peroxidase (HRP) substrate 
Immobilon Forte (MilliporeSigma) was added and imaged using ChemiDoc MP (Biorad). 
Total protein images of the Stain-free gels were also imaged using ChemiDoc MP. 
Densitometry was calculated using Image Studio Lite (Licor, Lincoln, NE, USA). 
HMVEC-L conditioned media was concentrated four-fold using 10 kDa cutoff centrifugal 
filters (Microcon-10, MilliporeSigma). 
2.2.4 hTSG-6 ELISA   
Human TSG-6 (hTSG-6) levels in conditioned media supernatant (600 g, 5 min) 
were measured as previously described [118] using a sandwich ELISA that had 
previously been validated by TSG-6 small interfering RNA (siRNA) in human MSC [138] 
and ASC [118]. 96-well plates (Nunc MaxiSorp) were coated with rat anti-hTSG-6 
antibody (clone A38.1.20; Santa Cruz Biotechnology) diluted in 0.2 M sodium 
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bicarbonate buffer (pH 9.4) overnight. All steps including antibody coating were 
performed at room temperature with rocking. Plates were washed with buffered 
surfactant (WA126, R&D Systems) between each step. Blocking was performed by 
adding PBS with 0.25% BSA and 0.05% TWEEN-20 and rocking (1 h). Samples were 
then incubated for 2 h. HMVEC-L conditioned media was concentrated eight-fold using 
10 kDa cutoff centrifugal filters (Microcon-10). Detection was performed by adding 
biotinylated goat anti-hTSG-6 antibody (BAF2104, R&D Systems) for 2 h, Streptavidin-
HRP (DY998, R&D Systems) for 30 min, HRP substrate (DY999, R&D Systems) for 30 
min, and quenched using 1 M H2SO4. Absorbance at 450 nm (HRP activity) and 584 nm 
(background) were measured using a 96-well plate reader (Molecular Devices, San 
Jose, CA, USA).     
To normalize TSG-6 secretion relative to cell number, viable cell numbers were 
obtained by trypan blue exclusion and cell counting by hemocytometer. Standard curves 
were obtained using recombinant human TSG-6 (2104-TS-050, R&D Systems) mixed 
with the same FBS content present in the conditioned media. Standard curve calculated 
in the absence and presence of FBS (2%) (Figure 2.1) showed that addition of FBS 
reduced the magnitude of HRP activity. This observation may be due to the formation of 
TSG-6-HC covalent intermediate in the presence of FBS, an IαI source. Since IαI’s ~80 
kDa HCs are very large compared to 35 kDa TSG-6, formation of TSG-6-HC may 
sterically hinder binding by the capture or detection antibodies used in the sandwich 
ELISA. This steric hindrance may help explain why efforts to directly assay TSG-6 levels 
in human serum have been difficult [144]. 
2.2.5 Statistics  
In Chapters 2-4, ANOVA and Tukey’s multiple comparison tests were performed 
to determine statistical significance (GraphPad 6 Prism, GraphPad Software, La Jolla, 
CA, USA) unless a different test was specified. Data points from independent 
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experiments or individual mice (n ≥ 3), median, or mean +/- SD were graphed unless 
otherwise specified. Results were considered significant at P<0.05.  
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Figure 2.1. hTSG-6 ELISA standard curves  
hTSG-6 standard curves were obtained using recombinant hTSG-6 with or without the 
addition of FBS (2% FBS). FBS reduced the magnitude of HRP substrate color 
development. The presence of FBS, an IαI source, results in the formation of TSG-6-HC 
covalent intermediate. Our data suggests that the covalent linking to the large 80 kDa 
protein moiety may sterically hinder the binding of capture and detection antibodies, 
which would explain the reduction in HRP substrate color change. OD, optical density. 
Figure from Ni et al. [56], open source.   
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2.2.6 Measurements of messenger RNA (mRNA)  
Total ribonucleic acid (RNA) was extracted from cultured cells as previously 
described using Buffer RLT Plus lysis buffer and RNeasy Plus Mini Kit (Qiagen) [56]. 
1000-2000 ng of extracted RNA was used to synthesize complementary DNA (High-
Capacity cDNA Reverse Transcription Kit). To measure the levels of specific mRNAs, 
real-time quantitative polymerase chain reaction (qPCR) reactions was performed using 
the StepOnePlus platform with Taqman Universal PCR Master Mix and Taqman probe 
hTSG-6 (Hs01113602_m1). Relative mRNA expression was determined by the double 
delta comparative (ΔΔCt) method with 18s RNA as the loading control (Taqman 
Hs99999901_s1).   
2.2.7 Time-course of macrophage expression of TSG-6 in LPS-instilled mice  
Expression of mouse TSG-6 (msTSG-6), also known as TNFα-induced-protein 6 
(TNFAIP6), was obtained by Ensembl gene annotation in a previously published dataset. 
The detailed methods for generating the dataset, along with the analysis of the RNA-
sequencing (RNA-seq) dataset, and National Center for Biotechnology Information 
(NCBI) deposition were discussed previously [145]. RNA-seq analysis was performed on 
resident and bone marrow-derived, recruited alveolar macrophages obtained by flow 
cytometry sorting of bronchoalveolar lavage of IT LPS (20 μg / mouse) treated mice 
(C57BL/6, 10-12 week old; 0, 3, 6, 9, and 12 days post injury). Each of these murine 
alveolar macrophage studies were completed by Dr. William Janssen’s lab at National 
Jewish Health following Institutional Animal Care and Use Committee (IACUC) approved 
protocol.   
2.3 Results 
2.3.1 TSG-6 secretion by lung resident cells 
To determine which lung cells can produce TSG-6 during ALI, we investigated 
TSG-6 secretion by cultured lung macrophages, bronchoepithelial cells, and fibroblasts 
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(Figure 2.2). Since LPS was identified as a potent stimuli of TSG-6 secretion in myeloid 
cells [68, 140] and is encountered in the respiratory tract following instillation, we first 
measured TSG-6 secretion by human peripheral blood monocyte-derived macrophage 
(hPBDM) and alveolar macrophage (hAM) in response to vehicle or LPS stimulation by 
TSG-6 western blot analysis of conditioned media. We noted that LPS (50 ng/ml, 24 h) 
induced TSG-6 (38 kDa) and TSG-6-HC covalent intermediate (120 kDa) in both types 
of macrophages (Figure 2.2A). TSG-6-HC covalent intermediate readily formed in the 
presence of FBS, an IαI source, and was notably absent when FBS was omitted. 
Addition of either TNFα (20 ng/mL, 24 h), the eponymous TSG-6 stimulus, or LPS (50 
ng/mL, 24 h) upregulated TSG-6 secretion in hAM (Figure 2.2B) in a manner that 
paralleled the induction of TSG-6 transcript (Figure 2.2C). TSG-6 expression was 
induced ~4 fold with TNFα stimulation and ~25 fold with LPS. 
To ascertain whether the different lung cell types can secrete physiologically 
relevant amounts of TSG-6 in response to TNFα or LPS stimulus, we quantitatively 
compared levels of TSG-6 secretion by the different lung cell types with human ASC 
(hASC), which are known to prolifically secrete TSG-6 (Figure 2.2D). We noted a 
strikingly different pattern of TSG-6 induction between the myeloid hAM and the non- 
hematopoietic bronchoepithelial (BEAS-2B), lung fibroblast (Wi38), and stromal hASC. 
While hAM secreted substantially more TSG-6 in response to LPS than TNFα (LPS ~61 
ng/mL vs. TNFα ~23 ng/mL), all three non-hematopoietic cells were more responsive to 
TNFα than to LPS. With the exception of hASC, LPS failed to induce any TSG-6 
secretion in bronchoepithelial cells and lung fibroblasts. Of note, LPS-treated hAM 
secreted a substantial amount of TSG-6 (~61 ng/mL vs. ~11 ng/mL; LPS vs. veh, P < 
0.001) that was comparable to LPS-treated ASC (~49 ng/mL) and to TNFα-treated lung 
fibroblast (~47 ng/mL). 
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To assess whether AM also upregulate TSG-6 in vivo and to determine the 
relative difference in TSG-6 expression in resident AM vs. bone marrow-derived, 
recruited AM, we examined a previously published RNA-seq gene expression dataset of 
resident and recruited AM collected by bronchoalveolar lavage of IT LPS-treated mice 
(Figure 2.3) [145]. We found that TSG-6 expression was highest initially following injury 
at day 3 following LPS instillation in both types of AM and more robustly induced in 
recruited AM as compared to resident AM. 
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Figure 2.2. TNFα or LPS induction of TSG-6 in lung cells 
A. LPS (50 ng/mL, 24 h) stimulation of TSG-6 secretion into conditioned media by 
human peripheral blood monocyte-derived macrophages (hPBDM) and alveolar 
macrophages (hAM) were detected by TSG-6 western blot. TSG-6 (35 kDa) readily 
formed TSG-6-HC covalent intermediate (120 kDa) only in the presence of FBS (an IαI 
source), which was absent with 0% FBS. B-C. Stimulation of hAM TSG-6 secretion (B, 
24 h) and gene expression (C, 6 or 24 h) by vehicle (veh), TNFα (20 ng/mL), or LPS (50 
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ng/mL) was assessed by western blot and qPCR, respectively. D. Levels of secreted 
TSG-6 by hAM, lung fibroblast Wi38 cells, and bronchoepithelial BEAS-2B cells treated 
(24 h) with the same indicated stimuli as in C were quantified by ELISA and compared to 
that by adipose stem and progenitor cells (hASC). n = 3 independent experiments per 
group. Data analyzed by ANOVA with Tukey’s multiple comparisons. **P<0.01, 
***P<0.001, ****P<.0001. Figure from Ni et al. [56], open source. 
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Figure 2.3. TSG-6 expression in mouse AM during ALI  
Resident and bone marrow-derived, recruited AM were obtained by flow cytometry 
sorting of bronchoalveolar lavage of mice at multiple time points (0, 3, 6, 9, and 12 days 
post injury) during a time course of IT LPS-induced injury and resolution. In this 
previously published RNA-Seq dataset [145], TSG-6 expression was analyzed and 
presented as transcripts per million (TPM). Mean expression (n = 3 independently 
pooled samples, n = 4-7 mice in each pool) and error (SD) plotted. dpi, days post injury. 
TPM, transcript per million. ND, not detected. NA, not applicable. SD, standard 
deviation. Figure from Ni et al. [56], open source. 
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2.3.2 Microvascular endothelial TSG-6 expression and secretion 
In the vasculature, while the circulating myeloid cells neutrophils and monocytes 
have the capacity to secrete to TSG-6 [68, 140], the ability of endothelial cells to secrete 
TSG-6 has not been investigated. In light of gene expression data from human umbilical 
vein endothelial cells suggesting that IL1β may be a potential stimuli [140], we 
comprehensively measured human lung microvascular endothelial (HMVEC-L) secretion 
of hTSG-6 in response to TNFα, LPS, or IL1β.  In contrast to LPS, both TNFα and IL1β 
(20 ng/mL, 24 h) were able to stimulate hTSG-6 secretion with IL1β more substantially 
inducing both hTSG-6 (38 kDa) and hTSG-6-HC intermediate bands as assessed by 
western blot (Figure 2.4A). These differences were consistent with the trends of hTSG-6 
secretion (TNFα ~3 ng/mL vs. LPS ~7 ng/mL) assessed by ELISA (Figure 2.4B) and 
TSG-6 transcript (TNFα ~391 vs. LPS ~1459 relative fold induction) assessed by qPCR 
(Figure 2.4D) and compared to that of hAM (Figure 2.4C-D).   
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Figure 2.4. Inflammatory induction of HMVEC-L TSG-6 secretion and expression 
A-B. Stimulation of hTSG-6 secretion into HMVEC-L conditioned media by vehicle, 
TNFα, LPS, or IL1β (20 ng/mL, 24 h) was assessed by hTSG-6 western blot (A) and 
ELISA (B). Full growth media (EGM-2-MV) containing FBS, an IαI source, was used for 
the conditioned media, which allowed the formation of TSG-6-HC covalent intermediate 
(120 kDa). Total protein was imaged using Stain-Free technology. C-D The induction of 
hTSG-6 secretion (C, ELISA) and hTSG-6 gene expression (D, qPCR) by HMVEC-L 
was compared to myeloid hAM. ND, not detected. n = 3 independent experiments per 
group. Data analyzed by ANOVA with Tukey’s multiple comparisons. *P<0.01, **P<0.01, 
***P<0.001. Ni et al., manuscript submitted.   
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2.4 Discussion 
To assess which cells contribute to TSG-6 production during ALI and endotoxic 
shock, we compared TSG-6 secretion across different cell types using quantitative 
ELISA. Based on the findings that stromal cells prolifically secrete TSG-6, we were not 
surprised to see that cultured lung fibroblasts would be able to respond to TNFα by 
secreting TSG-6. But it was unclear whether the other cells would also induce secretion 
of TSG-6 in response to TNFα. Our findings that bronchoepiethelial BEAS-2B and lung 
fibroblast Wi38 cells produced more TSG-6 in response to TNFα and that alveolar 
macrophage produced more TSG-6 in response to LPS are consistent with previous 
observations that TNFα elicits a stronger TSG-6 response in non-hematopoietic cells 
and LPS elicits a stronger response in myeloid-derived cells [68]. This myeloid-specific 
response to LPS is likely due to the high expression of the LPS receptor TLR4 in 
myeloid cells [146] and would suggest that TSG-6 may be a paracrine effector in the 
myeloid innate immune response to gram negative bacterial respiratory infection. 
As airway epithelial cells and terminally differentiated alveolar macrophages are 
situated in the respiratory tract, they would be directly exposed to LPS or gram negative 
bacteria and TNFα secreted by activated AM and recruited neutrophils. Thus, the acute 
inflammatory environment of respiratory infection would be expected to provide optimal 
signaling for TSG-6 secretion throughout the respiratory tract. Similarly, TNFα 
upregulated throughout the lung interstitium during ALI would stimulate parenchymal 
TSG-6 secretion by stromal cells, infiltrated neutrophils, and both interstitial and 
recruited macrophages. Since IT LPS and IP LPS also induce microvascular 
permeability, this would allow the leak of serum IαI into lung interstitium and alveoli that 
will serve as HC substrate. Thus, ALI may potently induce HC-HA formation, and HC-HA 
formation in both the lung parenchyma and respiratory tract may be part of a protective 
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innate immune response to gram negative bacterial respiratory infection, a hypothesis 
addressed in Chapter 3.  
Sepsis is characterized by a cytokine storm that precipitates microvascular 
permeability, which can lead to life-threatening septic shock. Since microvascular 
endothelial cells are particularly affected by the cytokine storm, our finding that HMVEC-
L secreted TSG-6 in response to two key proinflammatory cytokines (TNFα and IL1β) 
increased systemically during sepsis [147] temporally places TSG-6 secretion during 
conditions of vascular barrier instability. Considering the number of microvascular 
endothelial cells lining the vascular beds and that myeloid cells (neutrophils and 
monocytes) make up 30-50% of circulating hematopoietic cells in plasma [148], 
endothelial cells likely work together with myeloid cells to make sizeable contributions to 
intravascular TSG-6 production. Given the enzymatic availability of HA-modifying TSG-6 
and the immediate availability of IαI, extensive and repeated HC-modification of HA can 
potentially occur during endotoxic shock, which is discussed in Chapter 4. Since TNFα 
and especially IL1β induce both HA synthesis and HA-dependent monocyte adhesion in 
endothelial cells [149], the concurrent TSG-6 and HA secretion may direct hematopoietic 
trafficking during systemic inflammation. 
Most studies of stromal progenitor cells (MSC and ASC), which highly express 
and secrete TSG-6, have been completed with the assumption that the other non-
stromal cells (i.e. macrophage) are not a major source of TSG-6 [150, 151]. Our finding 
that TNFα and LPS can upregulate TSG-6 secretion in terminally differentiated hAM and 
that LPS treated hAM secrete considerable amounts of TSG-6 adds these non-stromal 
cells to peripheral blood monocytes and monocyte-derived cells as sources of TSG-6 
[68, 140]. Therefore, MSC and ASC are not an exclusive source of TSG-6, and the 
potential myeloid contribution of TSG-6 should be considered during inflammation. 
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Chapter 3. Rapid clearance of HC-HA during resolving ALI  
3.1 Introduction 
With the discoveries that HC-HA regulates neutrophil trafficking in liver sinusoids 
during systemic LPS exposure [133, 134], and that HC-HA deficient mice were more 
susceptible to IP LPS-induced endotoxic shock [135, 136], one key question that 
remained unanswered was whether HC-HA also exerted a protective role during 
localized acute lung injury, where the inciting injurious agent would be in the respiratory 
tract instead of the vasculature. The discovery that TSG-6 secretion can be induced in 
LPS-treated hAM and TNFα-treated bronchoepithelial cells and lung fibroblasts (Chapter 
2.3 Results) suggested that TSG-6 induction in the lung may be part of the innate 
immune response to gram negative bacterial respiratory infection. This observation, 
together with the fact that both IP and IT LPS causes ALI, suggested that TSG-6 and 
HC-HA may also play a protective role during respiratory infection models of ALI. 
A second key unanswered question was whether TSG-6 catalyzed formation of 
lung HC-HA during ALI. In contrast to the numerable reports that HC-HA accumulates in 
pathological lesions of chronic lung diseases, the induction and kinetics of HC-HA 
formation during ALI had not been reported. To better understand lung HC-HA induction 
and kinetics, we performed a time course of ALI injury and resolution in vivo. To model 
gram negative bacterial respiratory infection, we administered either LPS or live gram 
negative bacteria PA. In this context, we investigated whether HC-HA plays a protective 
role during IT LPS-induced ALI using TSG-6 KO mice and littermate controls.  
3.2 Methods 
3.2.1 Animal husbandry 
All animal experiments were approved by the IACUC at National Jewish Health. 
TSG-6 HT mice (BALB/c background) were obtained from Stavros Garantziotis and were 
originally constructed by Dr. Katalin Mikecz [77]. TSG-6 KO was confirmed by 
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genotyping (Table 3-1) and demonstrated inability to form HC-HA, as originally and 
repeatedly described for these mice [56, 77, 126].  All studies were conducted using sex 
(both male and female)- and age (8-12 week old)- matched TSG-6 KO mice and wild 
type (WT) and heterozygous (HT) littermate controls.  Mice were kept in standard cages 
with ad libitum access to regular chow and water in regular mouse housing sectors with 
sentinel monitoring of murine pathogens and 12:12 light darkness cycling. Mice used for 
PA experiments were transferred and treated in biosafety level 2 (BSL2) housing 
sectors.  
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Primers Sequence 
10840 
5'-CAA TGT TAG CAC ATC TTA ACC TCT TT-
3' 
10839 5'-TTT GCT TAT GCG TCT TGC TG-3' 
oIMR7415 5'-GCC AGA GGC CAC TTG TGT AG-3' 
    
Primer sets Expected size 
10840 and 10839 Wild type = 327 bp. Mutant = no band 
oIMR7415 and 10839 Wild type = no band. Mutant = 215 bp. 
    
Expected results 
WT (only 327bp). HT (327, 215bp), and KO (only 215bp) 
    
PCR Reaction mix uL   
KAPA 2G HS Buffer 10   
Water 5.8   
Primer #1 (20uM each) 0.6   
Primer #2 (20uM each) 0.6   
1:10 diluted template 3   
    
PCR cycling 
Step # Temp Time Note 
1 94 2 min   
2 94 
20 
sec   
3 65 15sec -0.5 C per cycle decrease 
4 68 10sec   
5     repeat steps 2-4 for 10 cycles 
6 94 15sec   
7 60 15sec   
8 72 10sec   
9     repeat steps 6-8 for 28 cycles 
10 72 2 min   
11 10 hold   
 
Table 3-1. Genotyping of TSG-6 mice  
Jackson Laboratory’s TSG-6 mice genotyping strategy was followed. Two PCR 
reactions, one to identify WT allele presence and a second to identify KO allele 
presence, were utilized to assign a genotype for each mouse.  
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3.2.2 Mouse IT LPS- and PA- induced ALI  
E. coli O55:B5 LPS (20 μg, L2880) or live gram negative PA bacteria (2 x 106 
CFU, colony forming unit, PA01 strain) was administered in a 50 μL PBS vehicle that 
was intratracheally instilled in the morning. Instillates were given directly into the 
tracheas via a 22-gauage oral gavage needle (7920, Cadence Science, Cranston, RI, 
USA) with its distal 0.5 cm end bent 40° to expedite tracheal insertion. Palpation of the 
needle over the tracheal rings was used to confirm position inside trachea. PA was 
obtained from Dr. Fabienne Gally (National Jewish Health) who used stocks from Dr. 
Kenneth Malcolm (National Jewish Health) that were from Pseudomonas Genetic Stock 
Center (East Carolina University) [77]. PA was grown in Luria-Bertani broth (LB). A new 
PA culture was freshly inoculated in the morning from an overnight starter culture to 
obtain bacteria in the exponential phase of growth with minimal dead bacteria. PA was 
centrifuged and resuspended at the appropriate CFU dilution for instillation. CFU was 
confirmed by plating dilutions of PA on LB agar. Mice were weighed every day, for up to 
6 days post-instillation. Mice welfare were monitored twice daily per IACUC protocol.     
3.2.3 Lung parenchymal HC-HA formation 
Mice were euthanized by isoflurane overdose and then lavaged by 
bronchoalveolar route. Bilateral thoracotomy was next performed as secondary 
euthanasia. Lungs were then perfused via the right ventricle using 10 mL of blood bank 
saline. HC-HA was measured in these lavaged and perfused lungs as previously 
described [152] with minor modifications to increase throughput. Rather than individually 
mincing each lung, equal mass (50 mg) of flash frozen mouse lung tissue was 
homogenized in PBS for 3 min using Mini-Beadbeater-16 (Biospec, Bartlesville, OK, 
USA). Lung homogenates were treated with either 1 U of Streptomyces hyaluronlyticus 
(S. hyaluronlyticus) hyaluronidase (389561, MilliporeSigma) or PBS control (45 min, 
4 °C) with mechanical agitation. Treated homogenates were then centrifuged (13,000 g, 
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5 min, 4 °C) and cleared supernatants were then incubated (45 min, 37 °C) with 
mechanical agitation. Laemmli Buffer was then added to stop the digestion. The samples 
were separated by SDS-PAGE (Stain-free Criterion TGX 7.5% gels, Biorad) and 
transferred to Immobilon-P PVDF membrane (MilliporeSigma) using TransBlot Semi-Dry 
apparatus (Biorad) and 1X Towbin buffer (Biorad). All western blot wash steps were 
completed using Tris-buffered saline with 0.1% TWEEN-20. Blocking was completed in 
5% nonfat dried milk (1 h) and blot was probed using rabbit-anti-hIαI antibody (A0301, 
DAKO, Agilent, Santa Clara, CA, USA), which was validated for detecting mouse IαI and 
HC-HA formation in various tissues [77, 126]. Donkey anti-rabbit IgG-HRP (NA9340, GE 
Healthcare) secondary was used at 1:20,000 in TBS with 5% milk and 0.1% TWEEN-20. 
Stain-free total protein images were obtained and densitometry performed as described 
previously (Chapter 2.2 Methods).  
3.2.4 Measurements of whole lung messenger RNA (mRNA) 
Total RNA was extracted from whole lung using Trizol Plus RNA Purification Kit 
with on-column deoxyribonuclease (DNAse) digest (PureLink DNase). Lungs were 
homogenized in 1 mL Trizol using a Mini-Beadbeater-16 (Biospec). cDNA reverse 
transcription and qPCR were performed as described previously (Chapter 2.2 Methods). 
The following Taqman probes were used: msTNFα (Mm00443258_m1), msTSG-6 
(Mm00493736_m1) [153, 154], msHAS1 (Mm03048195_m1), msHAS2 
(Mm00515089_m1), msHAS3 (Mm00515092_m1), msHYAL1 (Mm00476206_m1), 
msHYAL2 (Mm01230688_g1), msTMEM2 (Mm00459599_m1), and msCEMIP 
(Mm00472921_m1). Relative mRNA expression was determined using the double delta 
comparative (ΔΔCt) method with 18s RNA as the endogenous loading control (Taqman 
Hs99999901_s1).   
 46  
3.2.5 HA histology  
Mice were euthanized by isoflurane overdose and bilateral thoracotomy. Lungs 
were perfused via puncture of right ventricle using 10 mL of blood bank saline. 18-gauge 
stainless steel cannulas were inserted into trachea to inflate the lungs with a PBS 
solution containing 4% paraformaldehyde (PFA) (15710, Electron Microscopy Sciences, 
Hatfield, PA, USA) and 0.33% low melting point agarose. Inflated lungs were then tied 
and immersion-fixed overnight in 4% PFA (1 d, 4 °C) with gentle rocking and then 
washed with PBS (4 x 30 min) and incubated in PBS containing 25% sucrose and 25% 
optimal cutting temperature (OCT) compound (6 h). Lungs were then embedded in OCT 
compound and then sliced at 10 μm thickness. Sections were allowed to air dry before 
rinsing in PBS to remove OCT compound.    
Lungs from PA-treated mice were inflated with 10% neutral buffered formalin 
containing 0.25% low melting point agarose and fixed by full submersion in 10% neutral 
buffered formalin (overnight, room temperature). Fixed lung was paraffin embedded, cut 
at 3 μm thickness, and mounted on slides. Slides then underwent the following 
processing: deparaffination and rehydration using successive incubations in xylene (3 x 
5 min), 100% ethanol (2 x 5 min), 95% ethanol (2 x 5 min) and equilibration in PBS 
followed by water. Antigen retrieval was performed by placing slides in a pressure 
cooker containing citric acid based antigen unmasking solution (Vector Labs, 
Burlingame, CA, USA) and microwaved.   
Staining was accomplished through the following steps. Sections were blocked in 
PBS with 3% BSA and 0.1% Triton X-100 (MilliporeSigma) and primary probes added. 
Biotinylated hyaluronan binding protein (50 μg/100 μl stock, 385911, MilliporeSigma), 
rabbit anti-human HC2 (NBP2-31750, Novus, Littleton, CO, USA), and rat anti-mouse 
CD68 (FA-11, Biolegend, San Diego, CA) were added at 1:100 and incubated 
(overnight, 4 °C). On the next day, washes were performed with PBS in Coplin jar with 
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rocking (3 x 10 min) and secondary antibody was added for 1 h at room temperature. 
Streptavidin Alexa Flour 488 (S-11223) was used at 1:1000. Cy3 donkey anti-rabbit 
(711-165-152, Jackson ImmunoResearch, West Grove, PA, USA) and Cy5 donkey anti-
rat (712-175-153, Jackson ImmunoResearch) were used at 1:2000. Slides were 
mounted using ProLong Gold AntiFade with 4’,6-diamidino-2-phenylindole (DAPI) and 
imaged using laser scanning confocal LSM 700 (Zeiss, Jena, Germany).  
3.2.6 Histologic ALI scoring  
Unlavaged mice lungs were perfused with 10 mL of blood bank saline. Left lung 
was inflated with 0.25% agarose in 10% neutral buffered formalin to 20 cm H2O and 
immersion-fixed in neutral buffered formalin (overnight, room temperature) [94]. To 
ensure representative sampling of the entire lung, the fixed lung was placed in a molding 
box, encased in agarose, and sliced transversely (lung apex to base, 3 mm thick). 
Transverse lung pieces were embedded together in paraffin, sectioned at 3 μm, 
mounted on slides, deparaffinized, and rehydrated as described above. Slides were then 
stained with Harris Hematoxylin (2 min), Clarifier 1 (1 min), Bluing reagent (1 min), Eosin 
Y (30 sec), dehydrated, and mounted. Lung processing and staining were performed by 
Erica Beatman in the Petrache lab. Paraffin embedding, block sectioning and slide 
mounting was performed by the pathology core (National Jewish Health).   
Slides were blindly scored by a pathologist (Cassie Xu, University of Colorado 
School of Medicine) following an American Thoracic Society ALI scoring system [94]. 4-5 
fields (400X total magnification) of each transverse lung piece (4-5 pieces total) were 
assessed for five weighted parameters of ALI injury and a final averaged score between 
0 (no injury) and 1 (most severe) was calculated for each mouse.             
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3.2.7 Expression time-course of genes implicated in HA breakdown in LPS-
challenged mice  
Gene expression of msHYAL1-2, msTMEM2, msCEMIP, and msCD44 in mouse 
resident and recruited alveolar macrophages was identified using Ensembl gene 
annotation of the previously described RNA-seq dataset (Chapter 2.2 Methods) [145].  
3.2.8 HA fragmentation assessment in whole lung  
HA fragmentation in perfused lung tissue was assessed using the protocol 
developed by Cleveland Clinic Program of Excellence in Glycoscience and previously 
described [155]. Non-lavaged lungs were perfused with 10 mL blood bank saline and 
flash frozen. 50 mg of lung tissue was proteolytically digested using Proteinase K (1 
mg/mL) resuspended in 100 mM ammonium acetate (pH 7.0) with 0.01% sodium 
dodecyl sulfate (24 h, 60 °C). GAG were precipitated using 100% ethanol and washed 
using 75% ethanol. GAG pellets were resuspended in 100 mM ammonium acetate and 
heated at 100 °C to inactivate Proteinase K. Nucleic acids were degraded with an 
overnight benzonase incubation (MilliporeSigma) and then warmed to 100 °C to 
denature benzonase. GAG was then precipitated with 100% ethanol and washed in 75% 
ethanol. GAG pellet was resuspended in 100 mM ammonium acetate and equally 
divided, with half left untreated and half treated with 0.2 turbidity reducing units (TRU) of 
S. hyaluronlyticus hyaluronidase (Seikagaku, amsbio, Cambridge, MA), which allows for 
confirmation that the GAG present is specifically HA. 
All samples were lyophilized using a rotovap and resuspended in formamide 
(MilliporeSigma) and then loaded on 1% agarose gel (SeaKem HGT Agarose, Lonza). 
Stains-All (MilliporeSigma) was used to stain the gel overnight (1.25 mg/200 mL in 30% 
ethanol). On the next day, the gel was equilibrated in water and destained using brief 
exposure to ambient light. Gels were imaged on ChemiDoc MP (Biorad) using the Cy5 
695/55 epi-fluorescence filter, which detects HA stained with Stains-All [156]. HA 
 49  
fragments were sized using a ladder consisting of Select-HA (Hyalose, Oklahoma City, 
Oklahoma, USA) of predetermined sizes (2500, 1000, 500, and 250 kDa HA) as well as 
the Select-HA HiLadder (Hyalose). ImageJ was used to analyze the distribution of HA 
staining and perform densitometry calculations as described before [157]. Due to the 
large pore size, agarose gel electrophoresis is optimally suited for resolving high and 
medium molecular weight HA (>200 kDa). Alternative methods such as chromatography 
and polyacrylamide gel electrophoresis can provide better resolution and quantification 
of LMW HA [158, 159]. 
3.2.9 Lung tissue HA staining and discontinuity quantification  
Confocal Z-stacks of HA-stained lung sections were de-identified for the 
treatment received and blindly scored by a pulmonologist (Victor Tseng, University of 
Colorado School of Medicine). 3-5 representative images (320 x 320 μm) of the left lung 
were taken from each mouse. For each image, the HA staining in the peri-broncho-
vascular interstitial area was sampled with five representative snapshots (9.4 x 9.4 μm). 
Max intensity Z projections were prepared within the Fiji distribution of ImageJ [160]. 
Roughness was derived from the surface area [161] of the plotted intensity of HA 
staining, which was calculated using the SurfCharJ plugin [162]. Normalized roughness 
was calculated by dividing the surface area by average staining intensity of the 
snapshot. Normalized roughness values across the representative snapshots were 
averaged to assign a score for each individual mouse.  
3.2.10 Bronchoalveolar lavage fluid (BALF) collection and flow cytometry  
Mice underwent tracheotomy with the insertion of an 18-gauge angiocatheter 
(4075, JELCO-W, Smiths-Medical, Minneapolis, MN). BALF was collected by five serial 
instillations (1 x 1 mL and 4 x 0.9 mL) of PBS containing 2 mM EDTA (a return of 4 mL 
of total BALF was consistently obtained). For calculating the total CD45+ count, 
representative aliquots of the five lavages were combined, blocked with CD16/CD32 
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(clone 93, eBioscience), and stained with CD45 (30-F11, Becton Dickinson or BD 
Biosciences, Franklin Lakes, NJ, USA). 100 μL of 1:10 diluted 123count eBeads 
(eBioscience) were added to stained cells. For the total cell count, centrifugation was 
avoided to minimize variability introduced by spinning and aspiration. With the known 
concentration of the added counting beads and the ratio of CD45+ events to counting 
bead events given by the flow cytometer, the concentration of CD45+ cells was 
calculated and multiplied by 4 mL to get the total CD45+ cell counts. 
For the BALF differential, the five lavages were centrifuged and cell pellets 
combined. Flow wash buffer consisting of PBS with 9% FBS and 0.5 mM EDTA was 
used to resuspend and wash cells. Cell pellet was resuspended in flow wash buffer 
containing CD16/CD32 (eBioscience) and the fluorescently-conjugated antibodies: CD45 
(30-F11, BD Biosciences), Ly6G (1A8, Biolegend), CD64 (X54-5/7.1, BD Biosciences), 
CD11c (N418, eBioscience), F4/80 (BM8, eBioscience), CD11b (M1/70, eBioscience), 
Siglec-F (E50-2440, BD Biosciences), CD4 (RM4-5, Biolegend), and CD8a (53-6.7, 
Biolegend). On the LSR II cytometer (BD Biosciences), a minimum of 20,000 (PBS 
group) and 100,000 (LPS group) CD45+ leukocyte events were collected for each 
sample. Raw flow cytometry data was exported and analyzed in FlowJo software 
(FlowJo, Ashland, Oregon, USA). Schematic of gating used for BALF differential and 
CD45+ total cell counts is depicted (Figure 3.1).   
3.2.11 ELISA 
To measure albumin-, receptor for advanced glycation end products (RAGE)-, 
and HA, ELISAs were performed following manufacturer’s protocols: mouse albumin 
ELISA quantitation set (Bethyl Labs, Montgomery, TX); RAGE Duoset ELISA (R&D 
Systems); HA Duoset ELISA (R&D Systems). Combined supernatant obtained by 
pelleting (600 g, 8 min) the first three BALF aliquots (total 2.6 mL volume) was assayed 
using sample dilutions of 1:3000; 1:6; and 1:4 (control group) or 1:12 (LPS group), 
 51  
respectively. 96-well plates (Nunc MaxiSorp) were coated and were read as previously 
described for TSG-6 ELISA (Chapter 2.2 Methods).  
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Figure 3.1. Flow cytometry analysis of broncholaveolar lavaged leukocytes 
Bronchoalveolar lavage fluid (BALF) collected from a mouse (4 days post LPS 
instillation) is depicted to show all the recruited cells analyzed. A. Hematopoietic cells 
were identified by excluding debris and doublets and CD45+ staining. T cells were gated 
on CD3+ staining and distinguished by CD4+ CD8- and CD8+ CD4- staining. Neutrophils 
were gated as Ly6G+CD64- cells. Macrophages were gated as CD64+F4/80+ cells and 
differentiated as resident (CD11blowCD11c+SiglecF+) or recruited (CD11b+CD11clow). B. 
Counting beads were gated using their unique light scatter profile (SSChiFSClo) and 
fluorescently embedded dyes (FITC+PE+). Figure from Ni et al. [56], open source.  
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3.3 Results 
3.3.1 Lung parenchymal HC-HA induction and clearance  
To ascertain the kinetics of HC-HA induction during respiratory infection-induced 
ALI, we intratracheally administered either LPS (20 μg) or PA (2 x 106 CFU) and 
collected lavaged and perfused lungs from two timepoints, initial injury (1 day post LPS 
or 2 day post PA) and resolution phase (4 days post injury), for measuring HC-HA 
content. We treated homogenized lung with hyaluronidase (1U, HAse), which would 
release any HC linked to HA by degrading all HA into disaccharides. Using an IαI 
western blot, we were able to detect and quantify the robust release of HC initially after 
LPS (1 day post injury, Figure 3.2A) or PA (2 days post injury, Figure 3.2B) challenge, 
which suggest rapid and extensive lung parenchymal HC-HA formation. But by 
resolution phase (4 days post injury) after either LPS or PA challenge, released HC was 
largely absent, which suggests rapid clearance of HC-HA during resolving ALI. To 
confirm the role of TSG-6 as the exclusive mediator of HC-HA formation, lungs from 
TSG-6 KO and littermate controls (WT and HT) exposed to IT LPS and collected 1 day 
post injury were assessed for their HC-HA content (Figure 3.2C). As expected, released 
HC was notably absent in TSG-6 KO mice lungs when compared to control lungs, which 
confirmed TSG-6’s exclusive enzymatic function and validated the TSG-6 KO mice.  
After demonstrating rapid HC-HA induction, we investigated whether the whole 
lung transcript levels of TNFα, the eponymous TSG-6 stimulus, and TSG-6 were 
temporally associated with HC-HA induction during ALI. Both whole lung msTNFα 
(Figure 3.2D) and msTSG-6 (Figure 3.2E) were upregulated at 1 day post injury and 
returned to baseline levels at 4 days post injury in a manner that paralleled the induction 
of HC-HA: ~99 (1 day) vs. ~2 (4 day) relative fold msTNFα induction and ~3 (1 day) vs. 
~1 (4 day) relative fold msTSG-6 induction. While HC-HA accumulates in established 
interstitial lesions of chronic lung diseases, the location of HC-HA induced during 
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resolving ALI is unknown. To determine the localization of HC-HA, we co-stained 
sections of PA-challenged lung with probes for HC and HA (Figure 3.3). We found that 
HC appeared in peri-broncho-vascular regions and co-localized with HA at both 1 and 2 
days following IT PA injury, which was in agreement with the HC-HA induction noted in 
the homogenized lung. 
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Figure 3.2. Lung parenchymal HC-HA formation after LPS or PA injury 
A-C. Lung parenchymal HC-HA content was assessed by homogenizing 
bronchoalveolar lavaged and perfused lung tissue and treating with PBS (-) or 
hyaluronidase (+) to liberate any HC linked to HA, which can be detected by IαI western 
blot. Each mouse lung (pair of + and – HAse lanes) was isolated following exposure to IT 
LPS (20 μg, A) or PA (2 x 106 CFU, B) at an acute and a resolution time point and 
compared to PBS control. C. The role of TSG-6 as the exclusive mediator of HC-HA 
formation was confirmed by assessing the absence of HC-HA content in TSG-6 KO mice 
tissue collected 1 day post injury after IT LPS and comparing to littermate controls (WT 
and HT). D-E. Whole lung msTNF (D) and msTSG-6 (E) transcript levels from mice 
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exposed to indicated treatments were measured by qPCR. WT, wildtype. HT, 
heterozygous. KO, knockout. dpi, days post injury. n = 4-8 mice per group. Data 
analyzed by ANOVA with Tukey’s multiple comparisons. **P<0.01, ***P<0.001, 
****P<.0001. Figure from Ni et al. [56], open source. 
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Figure 3.3. Distribution of HC and HA staining after PA injury 
Sections of lung isolated from mice after exposure to IT PA (1 or 2 days post injury) or 
uninjured control (0 days post injury) were stained with HA binding protein (green) and 
HC2 antibody (red). Nuclei were stained by DAPI (blue). White arrows denote 
colocalization of HC and HA staining (yellow) in the peri-broncho-vascular interstitium. 
2nd antibody only staining (bottom row) was performed as a control. Br, large airway 
bronchus. V, vessel. Scale bar, 50 μm. Figure from Ni et al. [56], open source. 
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3.3.2 HA turnover and remodeling during ALI 
Since HC-HA was rapidly induced after injury and then absent by the onset of 
resolution of ALI (4 days post injury), we investigated whether active HA breakdown was 
induced during ALI. To investigate the molecular weight distribution of HA, we extracted 
glycosaminoglycans (GAG) from lung tissue taken from mice at two time points (1 or 2 
days post injury) following IT LPS (20 μg) exposure or PBS control, separated the 
polysaccharides by size under agarose gel electrophoresis, stained the polysaccharides 
with Stains-all, and performed densitometry (Figure 3.4). Samples treated with 
hyaluronidase (0.2 TRU, HAse) were analyzed to confirm specific HA staining. 
Additionally, as the largest GAG, high and medium molecular weight HA (2500-250 kDa) 
have no overlap with other GAG, which are all smaller than 50 kDa. In contrast to the 
abundance of HMW HA fragments (1000-2500 kDa) in PBS control, immediately 
following LPS challenge (1 or 2 days post injury), a large amount of HMW HA was 
replaced with an increasing amount of medium molecular weight HA fragments (250-500 
kDa).  
No striking differences in HA fragment distribution between TSG-6 KO and HT 
mice were observed, which would suggest that the increase in medium molecular weight 
fragments appeared independently of HC-HA formation (Figure 3.5A). Additionally, total 
HA content in the BALF measured by ELISA (which detects HA fragments of all sizes 
with a minimum limit of detection between 6 KDa and 15kDa [163]) was upregulated 
initially after injury (1 day post injury) and largely returned to baseline during the two 
resolution time points (4 and 6 days post injury). This finding suggests active HA 
clearance in the respiratory tract (Figure 3.5B). No difference in the levels of HA content 
was noted between TSG-6 KO and control (WT and HT) to suggest that HC-HA 
formation had any effect on HA turnover. Together, these results suggested that HA 
fragmentation and clearance occurred independently of HC modification.  
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Having demonstrated induction of HA breakdown and turnover during ALI, we 
investigated whether interstitial HA staining in lung sections underwent morphologic 
changes after LPS exposure. Lungs from mice exposed to LPS (20 μg, 4 days post 
injury) were stained with HA binding protein and compared to PBS control (Figure 3.6A-
B, Figure 3.7). While the pattern of HA staining appeared lamellar in texture in uninjured 
lungs, LPS injury induced a switch to more punctate and granular HA staining. To 
quantify the morphologic changes that are thought to represent HA remodeling driven by 
HA synthesis and fragmentation, we generated surface intensity plots of HA staining and 
measured the surface roughness. LPS injury significantly (P<0.05) increased the 
roughness of HA staining (Figure 3.6C). 
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Figure 3.4. Lung HA molecular weight distribution after LPS injury 
A. Stains-All detection of HA extracted from lung tissue of mice exposed to LPS (1 or 2 
days post injury) or PBS control and resolved by agarose gel electrophoresis. Samples 
were divided in half and treated in parallel with hyaluronidase to confirm that HA was 
specifically stained. Select-HA of the following sizes (2500, 100, 500, 250 kDa) and 
Select-HA HiLadder were used to size HA. B. Distribution of HA staining (mean +/- SEM) 
A
B
PBS
LPS
- Hyaluronidase
1 dpi 2 dpi PBS
LPS
+ Hyaluronidase
1 dpi 2 dpi
2500kDa
1000kDa
500kDa
250kDa
1510kDa
1090kDa
572kDa
495kDa
966kDa
H
A 
ab
un
da
nc
e
(A
U
)
8
6
4
0
C
2
PBS 1 dpi 2 dpi
LPS
H
A 
ab
un
da
nc
e
(A
U
)
50
40
20
0
10
30
PBS 1 dpi 2 dpi
LPS
2500 1000 500 250
H
A 
ab
un
da
nc
e
(A
U
)
1.0
0.8
0.6
0.4
0.2
0.0
PBS LPS 1 dpi LPS 2 dpi
 61  
by molecular weight was quantified by densitometry in ImageJ and plotted. C. 
Abundance of high and medium molecular HA staining was determined by integrating 
the area of HA abundance over specified size ranges. Data analyzed by ANOVA with 
Tukey’s multiple comparisons. *P<0.01, **P<0.01. Figure from Ni et al. [56], open 
source.  
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Figure 3.5. Effect of TSG-6 on lung HA molecular weight and lavage levels  
A. Stains-All detection of HA isolated from lung tissue of TSG-6 HT and KO mice 
exposed to LPS (1 day post injury) or PBS control and resolved by agarose gel 
electrophoresis. B. Total HA content in BALF was analyzed by ELISA during a time 
course of LPS injury and resolution (1, 4, or 6 days post injury) and compared to PBS 
control. n = 4-10 mice per group. Data analyzed by ANOVA with Tukey’s multiple 
comparisons. ****P<.0001. Figure from Ni et al. [56], open source. 
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Figure 3.6. Morphological changes in interstitial HA staining after LPS injury 
A. Identification of prominent HA staining in peri-broncho-vascular interstitium bordered 
by bronchi (Br) and blood vessels (V) in paraformaldehyde-fixed, frozen lung sections of 
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mice exposed to LPS 4 days post injury or PBS control that were stained with HA-
binding protein (green), macrophage marker CD68 (white), and nuclear stain DAPI 
(blue). A section stained with only the secondary probes is shown in the bottom row as 
control. Surface plots of the maximum intensity Z-projections of 9.4 x 9.4 μm interstitial 
areas were graphed and depicted on the right, measured in arbitrary units (AU). Scale 
bar, 50 μm. B. Line profile of HA staining in a max intensity Z-projection of a 
representative 50 x 50 μm area from the two treatments groups. C. Normalized surface 
roughness of HA staining was determined by dividing the surface area of staining by 
average staining intensity and compared between the indicated treatment groups. n = 3 
mice per group. Data analyzed by Student’s T-test. *P<0.01. Figure from Ni et al. [56], 
open source. 
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Figure 3.7. HA staining after LPS injury 
A. Images of the paraformaldehyde-fixed, frozen lung sections stained with HA-binding 
protein (depicted in Figure 3.6) shown in more detail. Morphological changes were 
observed for HA staining in the peri-broncho-vascular interstitium (white arrow). 
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Bronchus (Br) and large vessel (V) depicted. B. Representative sections from 
independent mice (n = 3 mice per group). Scale bar 50 μm. Figure from Ni et al. [56], 
open source. 
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 To better understand the active HA turnover and morphological changes in HA 
staining suggestive of HA remodeling, we investigated the transcript levels of genes 
encoding key enzymes responsible for synthesizing and breaking down HA. In whole 
lung tissue, expression of all three HA synthases (HAS1-3) were initially upregulated at 1 
day post LPS (msHAS1 ~2, msHAS2 ~5, and msHAS3 ~3 relative fold induction, 
respectively) and returned to baseline (msHAS1 ~0.3, msHAS2 ~1, and msHAS3 ~1 
relative fold induction, respectively) by 4 days post injury (Figure 3.8A). In contrast, the 
two key somatic hyaluronidases (HYAL1-2) were downregulated initially and during 
resolution (Figure 3.8B). Two genes, TMEM2 and CEMIP, encoding a HA degrading 
enzyme and a HA-binding protein recently implicated in HA endocytosis and 
degradation, respectively, were also assessed (Figure 3.8C). While msTMEM2 was 
consistently suppressed (1 day ~0.7 vs. 4 days ~0.7 relative fold induction), msCEMIP 
was upregulated initially and returned to baseline (1 day ~4 vs. 4 days ~1 relative fold 
induction).  
The steady clearance of HA in BALF with the resolution of inflammation (Figure 
3.5B) suggested the presence of cells in the respiratory tract that actively cleared HA. 
Since alveolar macrophages (AM) can bind and degrade HA [164], we analyzed the 
previously described RNA-seq dataset (Chapter 2.2 Methods) to assess the transcript 
abundance of genes implicated in HA breakdown in resident vs. recruited AM over the 
time course of IT LPS-induced ALI and resolution. In contrast to whole lung, we found 
stable expression of msHYAL1-2 and early induction of msTMEM2 in both types of AM 
that peaked at 3 days post injury and fell to baseline with resolution of inflammation 
(Figure 3.5D). Unlike the abundant levels of msHYAL2 and msTMEM2, msHYAL1 was 
minimally expressed and msCEMIP levels were below the one transcript per million 
threshold cut-off. Since HYAL2’s ability to degrade HA requires CD44 to first bind HA at 
the cell surface [33, 34], CD44 expression was analyzed and found to be very highly 
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expressed (Figure 3.5E). In contrast to msTMEM2, msCD44 expression in both resident 
and recruited AM steadily increased during resolution to reach peak levels on day 12 
post injury.          
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Figure 3.8. Effect of ALI on genes implicated in HA synthesis and breakdown 
A-C. Whole lung transcript levels of genes implicated in HA synthesis (HAS1-3) and HA 
breakdown (HYAL1-2, TMEM2, and CEMIP) during a time course of LPS-induced ALI 
and resolution, assessed by qPCR. n = 5-8 mice per group. D-E. Resident and recruited 
AM expression of genes implicated in HA degradation (HYAL1-2, TMEM2, CD44), 
assessed by RNA-seq. TPM, transcript per million. Data analyzed by ANOVA with 
Tukey’s multiple comparisons. *P<0.01, **P<0.01, ***P<0.001, ****P<0.0001. Figure 
from Ni et al. [56], open source. 
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3.3.3 Effect of HC-HA on ALI outcomes 
 Since HC-HA is implicated in neutrophil trafficking and survival outcomes during 
systemic LPS exposure and its associated ALI, we utilized TSG-6 KO mice to investigate 
the effect of HC-HA during localized IT LPS-induced ALI. We first examined the effect of 
HC-HA on weight loss severity and rate of recovery and noted no difference between 
TSG-6 KO mice and HT control (Figure 3.9A). To assess the impact of HC-HA on lung 
inflammation, we then assessed the abundance of lavaged inflammatory cells in the 
respiratory tracts by flow cytometry. In response to IT LPS (20 μg) challenge, absolute 
BALF counts of total hematopoietic (CD45+), neutrophils (Ly6G+), recruited 
macrophages (F4/80+CD64+CD11b+), CD4+ T cells, and CD8+ T cells were largely 
similar between TSG-6 KO and control (WT and HT) (Figure 3.9B-F). Total CD45+ 
hematopoietic cells and Ly6G+ neutrophils peaked at day 1 post LPS: uninjured ~2.2 x 
105 vs. 1 day ~1.4 x 106 CD45+ cells; uninjured ~2 x 103 vs. 1 day ~1.2 x 106 Ly6G+ 
neutrophils. As their numbers were dropping by day 4 of resolution, greater CD45+ (KO 
1.3 x 106 vs. WT 1.0 x106, p=0.013) and Ly6G+ (KO 13 x104 vs. WT 5.1 x 104, p=0.13) 
counts were noted in TSG-6 KO mice compared to control, which can result from a 
delayed onset in resolution. To confirm the BALF cellularity data findings, we measured 
in BALF the levels of albumin, a marker of microvascular endothelial damage (Figure 
3.9G), and RAGE, a marker of airway epithelial damage (Figure 3.9H), by ELISA. No 
differences in albumin or RAGE levels were noted between TSG-6 KO and control (WT 
and HT). Histologic evaluation of the extent of ALI resolution by 4 days following LPS 
was performed by hematoxylin and eosin staining of paraffin-embedded, formalin-fixed 
lung sections and blinded scoring for lung injury severity by a pathologist familiar with 
current recommendations [94] (Figure 3.10). We saw no evidence that lung injury 
scores were significantly different between TSG-6 KO and WT mice (Figure 3.10A). 
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 Finally, we examined the effect of HC-HA during a time course of PA infection (2 
x 106 CFU, IT) in order to validate our findings in a live gram negative bacterial infection 
model. Similar to our findings with IT LPS challenge, there were minimal differences in 
absolute neutrophil counts (Figure 3.11A) or albumin levels (Figure 3.11B) in BALF 
collected from TSG-6 KO vs. HT harvested at the following time points (2, 4, and/or 6 
days) following IT PA challenge compared to IT PBS control. There was a trend toward 
increased BALF neutrophil count (KO ~11 x 106 vs. HT ~7 x 106 Ly6G+, p=0.049) and 
albumin levels (KO ~1000 ng/mL vs. HT ~600 ng/mL, p=0.086) in TSG-6 KO 2 days 
after PA challenge. Together with the finding above that CD45+ and Ly6G+ counts were 
greater (15% more CD45+ in KO vs. HT, p=0.096; 13% more Ly6G+ in KO vs. HT, 
p=0.34) in TSG-6 KO 4 days after LPS, our results suggest that TSG-6 and HC-HA plays 
a modest protective role during IT LPS and PA challenge.        
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Figure 3.9. Effect of TSG-6 on severity and resolution of LPS-induced ALI 
A. Rate of weight loss and recovery in TSG-6 KO and HT during time course of IT LPS-
induced ALI. B-F. Total counts of inflammatory cells in BALF of TSG-6 KO mice and 
control littermates (WT and HT) during time course of LPS injury determined by flow 
cytometry. Total hematopoietic cells were gated by CD45+ staining. Neutrophils were 
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gated by CD45+Ly6G+ staining. Recruited CD11b+ macrophages were gated by 
CD45+F4/80+CD64+CD11b+ staining. CD4+ T cells were gated by CD45+CD3+CD4+ 
staining. CD8+ T cells were gated by CD45+CD3+CD8+ staining. G-H. Levels of albumin 
and RAGE in BALF of TSG-6 KO mice and control littermates (WT and HT) during time 
course of LPS injury, as assessed by ELISA. n = 3-8 mice per group. Data analyzed by 
ANOVA with Tukey’s multiple comparisons. **P<0.01, ****P<0.0001. Figure from Ni et al. 
[56], open source. 
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Figure 3.10. Effect of TSG-6 on histological injury scores of LPS-induced ALI 
A. Histological ALI scoring of TSG-6 KO and WT mice challenged with LPS (4 days post 
injury) compared to PBS control. n = 3-5 mice. B. Formalin-fixed, paraffin-embedded 
mice lungs were sectioned and stained with hematoxylin and eosin and scored at high 
power fields (400X). Blue arrowhead denotes neutrophils (4 days after IT LPS). C. 
Representative images taken at low power fields (100X and 200X) of lung sections from 
the following mice: TSG-6 KO or WT 4 days after IT LPS compared to IT PBS control. 
Scale bars: 25 μm (400X), 50 μm (200X), and 100 μm (100X). Data analyzed by ANOVA 
with Tukey’s multiple comparisons. ***P<0.001. Figure from Ni et al. [56], open source.  
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Figure 3.11. Effect of TSG-6 on severity and resolution of PA induced ALI 
A. Absolute count of neutrophils (CD45+Ly6G+) in BALF, following 2, 4, 6 days post PA 
injury (2 x 106 CFU, IT), assessed by flow cytometry. B. Levels of albumin in BALF 
following 2 or 4 days post PA injury, assessed by ELISA. n = 3-4 mice per group. Data 
analyzed by ANOVA with Tukey’s multiple comparisons. ****P<0.0001. Figure from Ni et 
al. [56], open source.   
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3.4 Discussion 
This study is the first to characterize the remarkable kinetics of lung parenchymal 
HC-HA induction and clearance during two resolving models of respiratory infection-
induced ALI. We found that the rapid clearance of HC-HA was associated with induction 
of active HMW HA fragmentation, turnover, and histological changes suggestive of HA 
remodeling. We found that the rapid breakdown and clearance of HA occurred 
independently of HC-modification. Our reports are consistent with previous observations 
that lung HA undergoes a high rate of turnover during both homeostasis and 
inflammation [25, 26].  
Our results are in striking contrast to the histopathological accumulation of HC-
HA in lesions of various chronic lung diseases. This difference may be due to our 
models of IT LPS and PA-induced ALI are fully reversible and do not lead to 
fibroproliferative lesions as seen in ARDS patients. A key difference between ARDS and 
our resolving models of ALI is the repeated and continuous mechanical ventilation-
induced epithelial insult that can trigger the fibroproliferative response in ARDS. A 
hallmark of chronic lung disease lesions is the deposition of collagen, which can envelop 
HA and HC-HA. It is conceivable that this collagen deposition may hinder access to 
hyaluronidase and ROS, which would allow HC-HA to accumulate instead of its 
clearance.   
Using TSG-6 KO mice deficient for HC-HA formation, we found that HC-HA only 
plays a modest protective role during both IT LPS- and PA-induced ALI. These results 
were surprising considering the key protective role of HC-HA in promoting survival 
during systemic IP LPS-induced endotoxic shock that has been demonstrated in both 
TSG-6 [135] and IαI [136] KO mice. But the discovery that HC-HA in the liver sinusoids 
can promote neutrophil adhesion during systemic LPS exposure suggests that HC-HA 
may be acting specifically in the vasculature during endotoxic shock. We address this 
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hypothesis in Chapter 4. Additionally, the lung compartmental localization of TSG-6 and 
levels of TSG-6 may be important. Using TSG-6 KO and littermate controls, we focused 
on the physiological role of endogenous TSG-6, which catalyzes the formation of lung 
parenchymal HC-HA. In contrast, exogenous TSG-6 given intratracheally has been 
associated with anti-inflammatory effects, which may be due to the ability of TSG-6 to 
bind neutrophilic chemokines [165, 166] or its potential ability to modify macrophage 
polarization [135, 151] via HA interactions with its CD44 receptor. However, the 
differences in lung macrophage polarization in TSG-6 KO vs. WT mice may be the result 
of markedly different inflammatory environments that can direct macrophage 
programming and functionality [135].  
Our study is the first to investigate the role of TSG-6 and HC-HA during bacterial 
respiratory infection-induced ALI. TSG-6 deficiency was associated with greater 
neutrophilic inflammation in both IT LPS and PA models. These differences in BALF 
neutrophil counts were noted either directly following (LPS, 4 days post injury) or during 
(PA, 2 days post injury) peak inflammation, which was characterized by extensive HC-
HA formation. Therefore, our results suggest that TSG-6 mediated HC-HA induction may 
have contributed to the protective effect seen with neutrophils. Considering the 
magnitude of the effect on BALF neutrophil counts and albumin levels, the protective 
effect of TSG-6 during ALI was modest. Given the importance of neutrophils in 
antibacterial defense [167-169], careful studies are needed with higher doses of PA to 
dissect whether TSG-6 and HC-HA are protective or harmful during gram negative 
bacterial ALI. While TSG-6 and HC-HA did not have huge effects on the outcomes of 
ALI, it is possible that they may be necessary for other injury and repair processes that 
require HA input including airway epithelial cell survival and homeostasis [170, 171]. 
Additionally, the rapid clearance of HC-HA during resolving ALI may have minimized the 
potential effects of HC-HA on lung injury and repair. Therefore, investigations with 
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experimental models that cause a more prolonged time course of inflammation and 
persistent HC-HA production are warranted to better understand HC-HA’s potential 
roles, which will be proposed in Chapter 5.2 Future directions.   
After our publication [56], similar results regarding kinetics of HC-formation and 
clearance during ALI have been reported with an IT influenza A (PR8 strain)-induced 
self-resolving respiratory infection model [172]: the highest HC-HA levels coincided with 
peak influenza inflammation (8 day post injury) and HC-HA was largely cleared by early 
resolution (14 days post injury) and absent at later time-points. In our IT LPS- and PA-
induced ALI models, the rise and clearance of HC-HA paralleled the trends in whole lung 
TNFα and TSG-6 transcript levels and alveolar barrier permeability as indicated by 
markers of epithelial and endothelial damage (RAGE and albumin). These results 
suggest that both the induction of TSG-6 and microvascular leak of serum IαI substrate 
contribute to rapid HC-HA formation. During resolution, the downregulation of TSG-6 
expression and the restoration of alveolar epithelial/endothelial barrier, which would 
prevent any further extravasation of serum IαI, would critically limit the formation of any 
additional HC-HA.   
While our results suggest that HC-HA has a minimal effect during resolving ALI, 
much work remains to fully understand the role of HA fragmentation and remodeling on 
lung injury outcomes and repair. Rapid clearance of HA and HC-HA may contribute to 
proper resolution of acute lung inflammation. Evidence for this idea comes from research 
using mice that found that IT administration of hyaluronidase accelerated recovery from 
influenza A infection [172] and hyaluronidase deficiency is associated with failure to 
clear HA and development of lung fibrosis [38].  
The rapid clearance of HC-HA was associated with breakdown of HMW HA 
and/or de novo production of medium molecular weight HA. While we did not distinguish 
between these two processes, the upregulation of whole lung HAS1-3 transcripts and 
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increase in BALF HA levels at 1 day post LPS instillation suggest that de novo HA 
production did take place. In contrast, levels of whole lung HYAL1-2 transcripts were 
consistently downregulated. These results did not agree with the induction of HMW HA 
fragmentation and clearance of HA in the BALF. However, our results are consistent with 
previous reports that whole lung HYAL1-2 expression may not accurately reflect actual 
HA turnover during inflammation [172, 173]. Instead, non-enzymatic ROS-mediated 
degradation of HA may play an important role in HA fragmentation during inflammation. 
While the precise in vivo contributions are unclear, the release of ROS by inflammatory 
cells can effectively degrade HA. Fragmentation of HA in vitro by activated neutrophils is 
almost completely inhibited by the addition of ROS scavengers [174]. Since ALI is 
characterized by significant neutrophil recruitment to lung tissue and alveoli, ROS would 
be expected to significantly contribute to HA degradation.  
HA-degrading membrane protein TMEM2 and the HA-binding CEMIP that 
promotes HA degradation via clathrin-mediated endocytosis have also been recently 
implicated in promoting HA turnover [48]. The two proteins, which are unrelated to 
HYAL1-2, are abundantly expressed in the lung [47, 48, 175] and thus may contribute to 
lung HA turnover. Whereas levels of whole lung TMEM2 transcript were suppressed 
following LPS challenge, expression of CEMIP mRNA paralleled the kinetics of HA 
fragmentation with highest expression at 1 day post injury, suggesting a potential role in 
HA turnover during peak neutrophilic inflammation.      
HA turnover during inflammation may be finely regulated by factors besides gene 
expression of HYAL1-2. For example, HYAL2 breakdown of HA requires CD44 binding 
of HA. CD44 can undergo a multitude of pre-mRNA splice variations, as well as post-
translational modifications that are differentially regulated in response to inflammatory 
stimuli, such as TNFα and LPS, which may in turn regulate its HA binding ability [176-
178].  
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Our analysis of resident and recruited AM transcripts revealed abundant 
expression of HYAL2, CD44, and TMEM2, which suggests a potential role for not only 
CD44 and HYAL2 working in concert to degrade HMW HA, but also TMEM2. TMEM2 is 
a recently discovered membrane protein with an ability to degrade HMW HA: of 
importance, TMEM2 features domains similar to bacterial polysaccharide lyases instead 
of HYAL1-2. Expression of TMEM2 in both resident and recruited AM was highest during 
the acute neutrophilic phase of inflammation (3 days post injury), which suggests a 
potential role in HA turnover during initial induction of HA fragmentation. In contrast, 
CD44 transcript in both resident and recruited AM steadily increased throughout the 
resolution phase and peaked at 12 days post injury following IT LPS challenge, which 
suggests a potential role of CD44 in HA clearance during resolution.  
Our results of upregulation of HAS1-3 in whole lung and downregulation of 
HYAL1-2 are consistent with the findings reported following influenza A infection [172]. 
In response to influenza A, peak lung inflammation is reached roughly one week after 
infection (8 days post injury). At this 8 days time point, exogenously instilled tagged HA 
was found to be cleared as rapidly as HA instilled into uninjured mice despite the whole 
lung downregulation of HYAL1-2. These findings support a model of additional HA 
degradation by ROS and other factors discussed above. Interestingly, during the later 
resolution phase (14 days post injury), exogenously instilled HA was found to be more 
rapidly cleared than during 0 or 8 days post injury. In the respiratory tract, enhanced 
clearance of HA during resolution may be attributed to increased tissue reparative 
programming of alveolar macrophages that can clear HA in contrast to a potential 
deficiency in HA binding and turnover during peak inflammation, which was noted during 
the time course of bleomycin injury [179]. This macrophage model is supported by the 
finding that HA clearance is impaired in CD44 KO mice following bleomycin challenge, 
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but can be rescued with WT bone marrow transplant and reconstitution with WT myeloid 
cells [180].  
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Chapter 4. Intravascular HC-modification of HA during endotoxic shock 
4.1 Introduction 
As both systemic and localized IT LPS exposure lead to lung microvascular 
permeability and ALI, we hypothesized in the previous chapter that HC-HA would also 
be protective during respiratory infection-induced ALI. Our finding that HC-HA plays only 
a minimally protective role during respiratory infection-induced ALI was surprising and in 
striking contrast to HC-HA being critically implicated in promoting survival and regulating 
neutrophil trafficking in the liver sinusoids during systemic LPS exposure [133, 134]. To 
address this discrepancy, we looked for differences in HC-HA induction between these 
two models focusing on the lung and plasma. Based on our experiments presented in 
Chapter 2.3 that suggested that microvascular endothelial cells are a potential vascular 
source of TSG-6 during septic cytokine storm, we hypothesized that systemic IP LPS-
induced shock uniquely stimulates intravascular HC-HA formation. Using TSG-6 KO 
mice, we determined that TSG-6 delayed the onset of mortality following systemic IP 
LPS-induced shock and investigated potential differences in markers of vascular 
inflammation. 
4.2 Methods 
4.2.1 Animal husbandry 
 All animal experiments were approved by IACUC at National Jewish Health. 
TSG-KO mice were previously described (Chapter 2.2 Methods). 
4.2.2 Mouse endotoxic shock model 
 E. coli O111:B4 LPS (L2630, MilliporeSigma) was resuspended in PBS as a 1.7 
mg/mL solution and administered as single IP bolus dose (20 mg / kg body weight [135]) 
injected in the right lower quadrant with a 26G x 3/8 needle, in the morning. Animal 
welfare and survival were evaluated every 6 h. Wet chow in petri dish was provided at 6 
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h post injury per IACUC approved protocol and veterinarian recommendations. Plasma 
and perfused lung were collected 8 or 12 h after IP LPS, as specified. 
4.2.3 Mouse IT LPS-induced ALI model 
 E. coli O55:B5 LPS (L2880, MilliporeSigma) was resuspended in PBS and 
administered as single instillation of 20 μg LPS in 50 μL PBS given in the morning as 
previously described (Chapter 3.2 Methods). Animal welfare and survival were evaluated 
twice daily per IACUC approved protocol. Mice were weighed daily up to four days after 
LPS challenge.   
4.2.4 Plasma collection and lung perfusion 
Mice were euthanized by isoflurane overdose first and then bilateral thoracotomy. 
Whole blood was removed by puncture of the right ventricle with a 1 mL syringe and 
needle (23G x 1 IM TW) containing 100 μL concentrated sodium citrate (S5770-50mL, 
MilliporeSigma). Lungs were then perfused through the right ventricle with 10 mL of 
blood bank saline, dissected, and snap frozen in liquid nitrogen. Whole blood was spun 
down (2000 g, 10 min, 12 °C), and the plasma supernatant was removed and frozen.     
4.2.5 Lung parenchymal and plasma HC-HA levels  
 Perfused lung tissue was homogenized and digested with 1 U of S. 
hyaluronlyticus hyaluronidase (MilliporeSigma) or PBS control as previously described 
(Chapter 3.2 Methods). Plasma (40 μL) was incubated with S. hyaluronlyticus 
hyaluronidase (1 U) or PBS control in warm water bath (2 h, 37 °C) and then with 
mechanical agitation (2 h, room temperature). Laemmli buffer was then added and equal 
volumes of plasma preparations were separated by SDS-PAGE, followed by western 
blot with the rabbit-anti-hIαI antibody as previously described (Chapter 3.2 Methods).      
4.2.6 Whole lung mRNA analysis 
RNA extraction from whole lung, cDNA synthesis, and qPCR were performed as 
previously described (3.2 Methods). The Taqman probes msTNFα (Mm00443258_m1) 
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and msCXCL2 (Mm00436450_m1) were used to measure the indicated gene 
transcripts. 
4.2.7 TSG-6 activity assay 
 Plasma was assayed for endogenous TSG-6 activity as described previously  
[152] with minor modifications. Plasma (40 μL) was incubated with 3 μg of 10-
oligosaccharide HA (HYA-OLIGO10EF-1, Hyalose, amsbio) for 2 h at 37 °C and then 
with mechanical agitation for 2 h at room temperature. Recombinant human TSG-6 (20 
ng, R&D Systems) was used as positive control. Negative controls were generated by 
mixing plasma with EDTA at a final concentration of 0.1M before adding 10-
oligosaccharide HA (HA10): TSG-6 enzymatic activity requires divalent metal cations 
Ca2+ and Mg2+ [57-59]. Samples mixed with Laemmli buffer were resolved by SDS-
PAGE, and western blot was performed using anti-IαI antibody, which can detect HC 
covalently linked to HA10 [152].    
4.2.8 Analysis of plasma by flow cytometry 
 Whole blood was similarly collected as above, but 0.5M EDTA (100 μL) was used 
instead as an anticoagulant (~83 mM final EDTA when added to ~500 μL blood draw). 
EDTA-treated whole blood (100 μL) was diluted with flow wash buffer solution (900 μL, 
PBS with 9% FBS and 0.5 mM EDTA) and spun (450 g, 4 °C) to pellet the cells. Packed 
cells were resuspended in 1 mL of red blood cell lysis buffer (Pharm Lyse, BD 
Biosciences) by pipetting up and down to lyse red blood cells. 1 mL of flow wash buffer 
and 5 mL of PBS was added to quench the lysis buffer and centrifuged. The cell pellet 
was resuspended in flow wash buffer solution containing CD16/CD32 (clone 93, 
eBioscience) and fluorescently conjugated antibodies: TER-119 (Biolegend), CD45 (30-
F11, BD Biosciences), Ly6G (1A8, Biolegend), CD11b (M1/70, eBioscience), Siglec-F 
(E50-2440, BD Biosciences), CD115 (AFS98, eBioscience). LSR II cytometer (BD 
Biosciences) was used to collect a minimum of 20,000 CD45+ leukocyte events for each 
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sample and raw data was analyzed in FlowJo software (FlowJo). Gating strategy 
depicted (Figure 4.4A).  
4.2.9 Mouse TNFα ELISA 
Plasma TNFα levels were measured using mouse TNFα DuoSet ELISA kit (R&D 
Systems) according to manufacturer’s instructions. Plasma from mice exposed to IP LPS 
were diluted with reagent diluent (1% BSA in PBS). 96-well plates (Nunc MaxiSorp) were 
coated and read as previously described (Chapter 2.2 Methods). 
4.3 Results 
4.3.1 Effect of TSG-6 on survival during endotoxic shock 
To confirm previous observations [135, 136] that HC-HA promotes survival 
during endotoxic shock, we administered a high bolus dose of LPS (20 mg / kg total 
body weight) via IP route that induces severe endotoxic shock and mortality (Figure 
4.1A). TSG-6 KO mice unable to form HC-HA exhibited more rapid onset of mortality 
than WT control: median survival of 18 h in KO vs. 21 h in WT. In contrast, following 
localized IT LPS (20 μg)-induced ALI, TSG-6 KO and WT control mice exhibited similar 
survival outcomes and speed of total body weight loss and recovery (Figure 4.1B).  
4.3.2 Lung parenchymal HC-HA formation after endotoxic shock 
 Since both IP and IT LPS administration cause ALI, we investigated HC-HA 
induction in both models. As previously described (Chapter 3.2 Methods), perfused lung 
tissue was homogenized and treated with hyaluronidase, which liberates any HC linked 
to HA for detection by IαI western blot. We found significant induction of HC-HA in lungs 
from mice collected 8 h after IP LPS (Figure 4.2A). To confirm that TSG-6 is the 
exclusive mediator of HC-HA formation and that our TSG-6 KO mice are valid, HC-HA 
content was assessed in TSG-6 KO mice and found to be absent when compared to 
control (Figure 4.2B). To compare the two routes of exposure, lung HC-HA content was 
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assessed 12 h after either IP or IT injury (Figure 4.2C). Both IP and IT routes were 
found to induce HC-HA formation with no significant differences between the two.  
 To control for the effect of HC-HA on lung inflammation in the two models, we 
assessed lung inflammation by measuring levels of TNFα transcript during an IT LPS 
time course (Figure 4.2D) or 8 h after IP LPS (Figure 4.2E) in TSG-6 KO vs. control 
(WT and HT) mice and compared to IP PBS. We additionally measured levels of 
neutrophilic chemokine CXCL2 8 h after IP LPS (Figure 4.2E). Neither marker of 
inflammation was statistically different in the two models, which suggests that lung 
parenchymal HC-HA, while significantly induced in both models, had a minimal effect on 
the outcomes of lung inflammation. 
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Figure 4.1. Effect of TSG-6 on survival during endotoxic shock  
A. Survival following IP LPS-induced endotoxic shock (20 mg / kg total body weight or 
TBW) was assessed over three days in TSG-6 KO and WT mice. n = 12-16 mice per 
group. Data analyzed with Log-rank (Mantel-Cox test). B. Survival and daily TBW 
change (mean +/- SD, % change from initial weight) following IT LPS challenge (20 μg / 
mouse) were assessed for four days. WT, wildtype. KO, knockout. dpi, days post injury. 
n = 5 mice per group. Data analyzed by ANOVA with Tukey’s multiple comparisons. 
Figure from Ni et al. [181], open source. 
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Figure 4.2. Lung parenchymal HC-HA after IP and IT LPS injury 
A-C. HC-HA content in homogenized lung tissue was assessed by hyaluronidase (HAse) 
digest which releases any HC linked to HA that can then be detected by IαI western blot 
analysis. Lungs were obtained from mice harvested 8 h after exposure to IP LPS (20 mg 
/ kg TBW) or IP PBS control, and released HC was quantified and normalized to total 
protein (A). HC-HA content was assessed in lungs from TSG-6 KO and WT mice 
collected 8 h after IP LPS exposure to confirm that TSG-6 is the exclusive mediator of 
HC-HA formation (B), as evidenced by the absence of released HC with TSG-6 
deficiency. HC-HA content was assessed in lungs obtained from mice harvested 12 h 
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after exposure to IP LPS, IT LPS (20 μg), or IP PBS control (C). D. Whole lung 
expression of msTNFα was assessed in TSG-6 KO and WT/HT mice during a time 
course of IT LPS-induced injury and resolution (LPS 1 or 4 days post injury) and 
compared to IT PBS control. E. Whole lung msTNFα and msCXCL2 were assessed in 
TSG-6 KO and control (WT and HT) mice 8 h after IP LPS exposure and compared to IP 
PBS control. n = 4-6 mice per group. Data analyzed by ANOVA with Tukey’s multiple 
comparisons. Figure from Ni et al. [181], open source. 
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4.3.3 Intravascular HC-HA and TSG-6 induction after endotoxic shock 
 Since vascular endothelial cells can respond to cytokines upregulated during 
sepsis by secreting TSG-6 (Chapter 2.3 Results), we investigated whether HC-HA was 
systemically induced after IP LPS (20 mg / kg TBW)-induced endotoxic shock. The 
presence of HC-HA in plasma was similarly assessed as in lung tissue by treating with 
hyaluronidase, which released any HC linked to HA that can be detected by IαI western 
blot. While HC-HA was robustly induced 12 h after IP LPS compared to IP PBS control, 
HC-HA was absent after IT LPS (20 μg, Figure 4.3A). As HC-HA is continuously cleared 
by the liver, the presence of HC-HA suggested continuous production of TSG-6 to 
generate additional HC-HA. To determine the presence of endogenous TSG-6 in 
plasma, we measured TSG-6 activity by adding 10-oligosaccharide (HA10) and 
assessing the formation of HC-HA10, which can be detected by IαI western blot (Figure 
4.3B). As a positive control, recombinant human TSG-6 (rhTSG-6) was tested to confirm 
that sodium citrate anticoagulant used to collect plasma did not inhibit TSG-6 activity 
(Figure 4.3B). The irreversible divalent metal chelator EDTA was used as negative 
control, because TSG-6 enzymatic activity requires the presence of divalent metal 
cations Mg2+ and Ca2+ [57-59]. When we assessed TSG-6 activity, HC-HA10 was induced 
after IP LPS compared to IP PBS control and noticeably absent following IT LPS (Figure 
4.3C: IP PBS ~1 vs. IP LPS ~5.6 vs. IT LPS ~1.7 normalized abundance, p<0.0001), 
which was in agreement with our observation that HC-HA was only induced after IP LPS.       
4.3.4 Vascular markers of inflammation in TSG-6 KO mice 
 While HC-HA promotes survival outcomes during IP LPS-induced systemic 
inflammation and regulates neutrophil trafficking locally in the liver sinusoids, the effect 
on neutrophils systemically had not been explored. Since we discovered that 
intravascular HC-HA is induced after IP LPS, we utilized TSG-6 KO mice to investigate 
whether HC-HA had any effect on circulating neutrophils numbers. Plasma was collected 
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8 h after IP LPS (20 mg / kg TBW) and flow cytometry was used to identify neutrophils 
and mononuclear cells (Figure 4.4A). IP LPS induced an increase in the percentage of 
circulating neutrophils (Ly6G+ / CD45+) after IP LPS (Figure 4.4B: IP LPS ~42% vs. IP 
PBS ~27%). Lack of HC-HA in TSG-6 KO mice tended to further increase the 
percentage of circulating neutrophils (Figure 4.4B: KO 46% vs. WT/HT 39%, p=0.27) 
and lower the percentage of circulating mononuclear cells (Figure 4.4C: KO 42% vs. 
WT/HT 49%, p=0.13) when compared to control. HC-HA deficiency in TSG-6 KO mice 
was additionally associated with a trend of greater circulating TNFα levels in plasma 
compared to control (Figure 4.4D: KO ~51 pg/mL vs. WT/HT 39 pg/mL, p=0.21). To 
ascertain potential effects of sex on circulating neutrophils during endotoxic shock, the 
results in Figure 4.4B were subdivided into male vs. female (Figure 4.4E). The 
tendency toward greater percentage of circulating neutrophils in TSG-6 KO mice was 
more pronounced in female mice and largely absent in male mice. As expected, the 
dose of LPS administered by IP route was higher on average for male mice due to their 
heavier weights and the strategy of dosing proportionally to TBW (Figure 4.4F).  
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Figure 4.3. Plasma HC-HA and TSG-6 activity after IP and IT LPS injury 
A. HC-HA content in plasma from mice 12 h after exposure to IP LPS (20 mg / kg TBW), 
IT LPS (20 μg), or IP PBS control was similarly assessed by hyaluronidase digest and 
IαI western blot. B. TSG-6 activity in plasma was measured by incubating with 10-
oligosaccharide HA (HA10) and assessing the formation of HC-HA10 by IαI western blot. 
Recombinant human TSG-6 (rhTSG-6) was used as positive control. Plasma pre-mixed 
with EDTA before adding HA10 was used as a negative control. C. HC-HA10 formation 
was assessed in plasma from mice exposed to the indicated treatments and quantified 
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by densitometry. n = 4 mice per group. Data analyzed by ANOVA with Tukey’s multiple 
comparisons. Figure from Ni et al. [181], open source. 
  
 95  
 
Figure 4.4. Effect of TSG-6 on circulating PMN and plasma TNFα  
A. Flow cytometry gating strategy used to identify neutrophils (polymorphonuclear cells 
or PMN) and mononuclear cells in the plasma. In the center, hematopoietic cells were 
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gated by debris and doublet exclusion and CD45+ TER-119- staining. Mononuclear cells 
including lymphocytes and monocytes were gated as SSCloLy6G-. PMN was gated as 
Ly6G+CD11b+SiglecF-. Eosinophils were gated as SSChiLy6G-CD11b+SiglecF+. B-C. 
Circulating abundance of PMN (B) and mononuclear cells (C) in plasma were expressed 
a percentage of CD45+ cells after indicated treatments. D. Plasma levels of TNFα 
cytokine after indicated treatments were measured by ELISA. n = 4-12 mice per group. 
E. Circulating PMN results of IP LPS plasma based on sex. F. Amount of LPS given by 
IP route (mean +/- SD) to male (n = 9) and female (n = 13) mice. LPS dose was 
calculated based on weight (20 mg / kg TBW). SD, standard deviation. Data analyzed by 
ANOVA with Tukey’s multiple comparisons. Figure from Ni et al. [181], open source. 
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4.4 Discussion 
 Sepsis is a serious condition characterized by a systemic inflammatory response 
for defeating bacteremia that also causes life-threatening endotoxic shock. In this 
chapter, we investigated how HC-HA can have a distinctly protective role during 
endotoxic shock in contrast to a minimal role during localized IT LPS exposure (Chapter 
3.3 Results). We showed for the first time that systemic IP LPS-induced endotoxic shock 
is characterized by the specific induction of intravascular TSG-6 and HC-HA, which were 
noticeably absent after localized IT LPS exposure. In contrast, both IP and IT LPS 
exposure non-specifically induced lung parenchymal HC-HA, which was expected 
because both models cause ALI. We noted that TSG-6 KO mice were more susceptible 
to endotoxic shock-induced mortality. Lack of HC-HA formation in TSG-6 KO mice was 
associated with tendency toward greater numbers of circulating neutrophils and plasma 
levels of TNFα, which suggest that greater systemic inflammation may have contributed 
to the increased susceptibility to mortality.  
Our finding that TSG-6 promotes survival during endotoxic shock is consistent 
with previous reports that TSG-6 and IαI KO mice exhibit greater mortality following 
systemic IP LPS administration [135, 136]. We followed the previously published 
endotoxic shock paper (same LPS preparation and 20 mg / kg TBW dosing strategy) 
[135] that had reported that TSG-6 KO mice display 100% mortality and WT mice 0% 
mortality at 24 h post IP LPS [135]. However, for this key result, since survival was not 
reported past 24 h, it is not known whether the 0% mortality result would still hold if 
survival was assessed over a longer time frame. This is an important concern, because 
depending on the effective dose, IP LPS-induced mortality can still occur later, after the 
first 24 hours, but during the first 96 hours, as reported by other experiments in the same 
paper [135] and by us (Figure. 4.1). Therefore, our survival findings may have been 
much closer to what had been published with regards to promoting survival. Since 
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overall we observed a more rapid onset of mortality, our actual effective LPS dose may 
have been higher despite our efforts to follow the same LPS dosing strategy. Thus, 
titrating down the LPS dose may better accentuate the physiologic differences during 
endotoxic shock between TSG-6 KO and WT control mice. This is especially relevant for 
male mice, who received a higher dose of LPS due to their reaching heavier body 
weights than female mice of the same age and may also respond differently due to sex 
differences [182]. In support of the premise that male mice did not receive an optimal 
LPS dose for discerning protective effects of HC-HA, the ability of HC-HA to decrease 
circulating percentage of neutrophils was limited to female mice. Other potential 
considerations include institutional differences in environmental and intestinal 
microbiota, which have been shown to influence the magnitude of inflammatory 
responses to IP LPS [167, 183].               
Our results expand on a previous effort to understand TSG-6 KO mice’s 
susceptibility to endotoxic shock that focused exclusively on differences in lung 
inflammation and lung macrophage polarization [135]. Since the key pathologic 
development during endotoxic shock is vascular barrier dysfunction and microvascular 
endothelial cells can respond to the septic cytokine storm by secreting TSG-6 (Chapter 
2.3 Results), we instead focused on the vasculature. Specifically, we addressed whether 
TSG-6 and HC-HA were specifically induced after systemic IP LPS, but not after 
localized IT LPS administration. The induction of TSG-6 and HC-HA in the vasculature 
may serve as an evolutionarily conserved endogenous innate immune response to 
sepsis to regulate hematopoietic cell trafficking and clearing bacterial infection during 
systemic inflammation. This model is supported by the discovery that HC-HA 
interactions with CD44 receptor enhanced neutrophil adhesion in the liver sinusoids 
during endotoxic shock [133, 134]. Enhanced neutrophil adhesion in the liver sinusoids 
may be beneficial in sepsis in many ways. Firstly, neutrophil adhesion may enhance 
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Kupffer cell clearance of damaged and apoptotic neutrophils, which would minimize 
unnecessary neutrophilic damage in other organs [107]. Secondly, adhered neutrophils 
may more effectively trap and kill their bacterial targets via extrusion of neutrophil 
extracellular traps [102, 103, 184].   
Robust intravascular HC-HA induction is likely specifically activated during sepsis 
and endotoxic shock. With the continuous clearance of circulating HA by the liver 
sinusoids (2.5-5 min half-life in plasma [27, 28]), the formation of small amounts of HC-
HA would be expected to be rapidly cleared. However, during endotoxic shock, the 
septic cytokine storm would induce robust TSG-6 secretion that can sustain substantial 
catalysis of intravascular HC-HA formation. Additionally, any shock-induced end-organ 
damage to the liver would result in decreased turnover leading to HC-HA accumulation. 
Evidence that robust HC-HA induction is a specific innate immune response of 
sepsis and endotoxic shock comes from the observation that either systemic LPS or live 
gram negative E. coli exposure induces HA/CD44-dependent neutrophil adhesion in the 
liver sinusoids and the specific retaining of adherent neutrophils in the liver sinusoids 
without emigrating out to liver tissue [109]. In contrast, during local injury to liver surface 
by the bacterial PAMP/DAMP N-formyl peptide, neutrophil adhesion in the liver sinusoids 
did not depend on HA/CD44 interactions and neutrophils emigrated into liver tissue 
[109]. These distinct results reveal how neutrophil trafficking and emigration into tissue 
are carefully regulated. When the site of liver injury is extravascular, adherent 
neutrophils emigrate into liver tissue. In contrast, during systemic LPS or E. coli-induced 
inflammation, adherent neutrophils stay in the liver sinusoids. This compartmentalization 
may be important, because if neutrophils emigrated into liver tissue during systemic 
inflammation in the absence of local injury, there could be unnecessary tissue damage. 
Additionally, these results highlight the involvement of other adhesion molecules (i.e. 
interactions between CD11b/CD18 integrin and ICAM-1 during localized liver injury) that 
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regulate neutrophil trafficking [109], which may help explain why HC-HA has a minimal 
role during localized IT LPS-induced ALI.   
The finding of intravascular TSG-6 and HC-HA induction during murine endotoxic 
shock likely extends to human sepsis, given the evolutionary conservation of TSG-6 
catalyzing HC-HA in all vertebrates [3, 72]. Additionally, the presence of TSG-6 in the 
serum of healthy patients systemically injected with LPS and hospitalized patients with 
sepsis has been reported as unpublished observation [185]. This induction of TSG-6 
secretion would be carried out by both circulating myeloid cells and endothelial cells 
stimulated directly by bacterial LPS or the pro-inflammatory cytokines of the septic 
cytokine storm, which we investigated (Chapter 2.3 Results). During the clinical course 
of sepsis, the initial pro-inflammatory response to bacteremia is quickly followed by a 
counterregulatory anti-inflammatory response [112]. Thus, intravascular TSG-6 secretion 
may peak shortly after the height of the septic cytokine storm and then drop 
precipitously. This presents an opportunity for identifying an optimal window to 
intravenously infuse TSG-6 as a therapeutic intervention to generate circulating HC-HA 
that may confer protection during the particularly vulnerable period after the initial 
admission of the septic patient.    
One caveat of interpreting our survival results was the recent demonstration in 
chicken and mouse that HC-HA plays an important developmental role in initiating 
vertebrate midgut rotation and that HC-HA deficient mice (TSG-6 or IαI KO mice) exhibit 
midgut malrotation [80]. While it was suggested that TSG-6 KO murine embryos may 
exhibit impaired viability due to midgut malrotation, we did not observe any impaired 
viability with TSG-6 KO mice pups (Chapter 1.2.2 TNFα Stimulated Gene-6) and two 
reports also independently confirmed that IαI KO mice pups exhibited normal Mendelian 
inheritance ratios [76, 82], which suggest that HC-HA does not reduce viability. These 
results agree with the clinical finding that most cases of intestinal malrotation do not lead 
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to life-threatening volvulus and strangulation [83, 84]. While our results suggest no 
deficits at baseline, these findings do not definitively rule out physiological impairments 
that may manifest during severe injury and stress, which may be encountered during 
endotoxic shock.  
The TSG-6 generation of HC-HA is ideally spatio-temporally situated in the ECM 
to signal and direct the inflammatory response to infection and injury [186]. HC-HA can 
interact with a multitude of cellular effectors of inflammation, because expression of the 
HA receptor CD44 is either constitutively expressed or inducible in most hematopoietic 
cells [11] and non-hematopoietic cells including epithelial [187], stromal [188], and 
endothelial cells [189]. In the vasculature, HA abundance is the greatest in the liver 
sinusoids, over 500-600 times more than the lung vasculature, which is second in HA 
abundance [133]. The high concentration of HA in the liver sinusoids may be due to its 
accumulation there as it awaits clearance by the sinusoidal endothelium via endocytosis 
and lysosomal degradation [51] [52]. Not surprisingly, liver sinusoids are also the 
location where HC-HA has been implicated in regulating neutrophil trafficking during 
endotoxic shock [134]. Intravascular HA likely undergoes dramatic changes during 
endotoxic shock due to increase in amounts of HA fragments of all sizes and covalent 
modification of all HA fragments, from HMW to those as small as 8-oligosacharides 
[190]. While the inflammatory consequence of generating a large amount of 
intravascular HA repeatedly modified with the HC is relatively unclear, IαI’s HC moiety 
may also be acting on other systemic processes, as evidenced by the findings that HC 
can regulate systemic complement pathway [64, 65] and neutrophil activation [66]. In 
this context, HA may serve as the scaffold for bringing together CD44 expressing cells 
for interacting with HC and undergoing HC-mediated effects.      
It is important to note that TSG-6 has putative functions besides its evolutionarily 
conserved role of covalently modifying HA. For example in ALI and endotoxic shock, 
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TSG-6 has been shown to bind and inhibit human neutrophilic CXCL8 [165, 166]. 
However, the same studies revealed the ability of TSG-6 to bind to a large number of 
CXC and CC family chemokines (CXCL4, CXCL12, CCL2, CCL5, CCL7, CCL19, 
CCL21, and CCL27), which raises the question of the in vivo significance of TSG-6 
binding any one particular chemokine during inflammation. The in vivo contribution of 
chemokine binding by TSG-6 is likely overshadowed by the predominance of GAGs, 
which are present in much greater quantities in the endothelial glycocalyx and have 
been demonstrated to bind and present chemokines to hematopoietic cells during 
inflammation [191-193].   
A key unanswered question is the potential role of HC-HA in the bone marrow 
during sepsis and endotoxic shock. Immunosuppression can occur in septic patients and 
bone marrow dysfunction may contribute to neutropenia and inability to fully clear 
remaining septic foci [112, 113]. While the role of HC-HA is unclear, HA interactions with 
its CD44 receptor appear to play an important role in promoting hematopoietic progenitor 
cell proliferation during conditions of bone marrow stress such as accelerating transplant 
engraftment following irradiation [117]. Additionally, our lab reported that exogenous 
TSG-6 supplementation can improve hematopoietic progenitor cell function after 
cigarette smoke-induced myelosuppression [118]. Other labs have shown using TSG-6 
supplementation or TSG-6 KO mice that TSG-6 can regulate bone marrow stromal cell 
differentiation [119-121]. Together, these findings indicate a potential role of TSG-6 and 
HC-HA in the bone marrow during sepsis and underscore the need to study potential 
bone marrow roles during conditions of systemic inflammation, which will be proposed in 
Chapter 5.2 Future directions.  
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Chapter 5. Conclusion 
5.1 Summary 
The inflammation-induced secreted enzyme TSG-6 mediates the sole covalent 
modification HA can undergo. Formed in the ECM during inflammation, HC-HA is spatio-
temporally positioned to regulate the inflammatory response to injury and infection. This 
thesis provides the first characterization of the remarkable kinetics and role of HC-HA 
during localized IT and systemic IP LPS exposures. In Chapter 2, we established the 
potential cellular sources of TSG-6 enzyme that would catalyze HC-HA formation in 
human lung and plasma during LPS-induced injury. Using TSG-6 KO mice, we next 
investigated the kinetics and role of HC-HA during IT LPS- and PA-induced ALI in 
Chapter 3. Lastly in Chapter 4, we pursued comparative studies of systemic vs. localized 
IT LPS exposure in mice to understand the unique roles of TSG-6 and HC-HA during 
endotoxic shock. 
Our finding that HC-HA is rapidly induced and cleared during two models (IT LPS 
and gram negative PA) of respiratory infection-induced ALI highlights the dynamic nature 
of HA turnover in the lung. While lung HA undergoes continuous turnover during 
homeostatic conditions, LPS injury uncovered a remarkable induction of HMW HA 
breakdown and increase in medium molecular weight fragments, suggestive of 
increased rate of turnover and/or de novo synthesis, which are likely both occurring due 
to the recruitment of neutrophils that can release HA-degrading ROS, initial increase in 
BALF HA levels, and upregulation of whole lung HA synthase transcripts. Following LPS 
injury, the lamellar and wavy pattern of HA staining of uninjured lung sections became 
punctuated and more rough, suggestive of active HA remodeling. Our results regarding 
the induction and clearance of HC-HA during ALI have since been replicated during 
influenza A-induced lung infection [172], which involved a longer time course due to the 
time it takes influenza A virus to propagate in the respiratory tract (peak inflammation by 
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8 day post injury and significant resolution without fibrotic complications by 14 days post 
injury).          
Pursuing comparative IT and IP LPS studies, we discovered how intravascular 
TSG-6 and HC-HA were specifically induced during endotoxic shock, whereas lung 
parenchymal HC-HA was non-specifically induced by both IT and IP LPS. Using TSG-6 
KO mice, we confirmed TSG-6’s protective role against endotoxic shock and expanded 
on a previous endotoxemic study with TSG-6 KO mice [135] that had focused 
exclusively on the lung tissue and lung macrophage polarization by investigating 
potential differences in the vasculature, which is the key site of physiologic dysfunction 
during endotoxic shock. We discovered that the presence of intravascular HC-HA was 
associated with decreased numbers of circulating neutrophils and plasma levels of TNFα 
suggestive of less vascular inflammation that may explain the greater protection noted 
during endotoxic shock.  
Our finding of intravascular TSG-6 during murine model of endotoxic shock is 
consistent with the unpublished observation that TSG-6 is present in the serum of 
healthy patients injected with LPS and hospitalized patients with bacteremia [185]. We 
further established the relevance of TSG-6 in human lung and vascular inflammation by 
using primary human cells and human cell lines to define potential sources of TSG-6. 
Our findings are the first to describe robust intravascular HC-HA induction during acute 
systemic inflammation. Intravascular HC-HA has only been previously shown in the 
serum of patients suffering from rheumatoid arthritis [194] and chronic liver disease 
[195], which are both associated with systemic vascular inflammation and dysfunction 
[196, 197] that would be expected to provide the appropriate inflammatory signals to 
induce TSG-6 to catalyze HC-HA formation. In the case of chronic liver diseases, there 
may also be deficits in liver HA clearance leading to the accumulation of HC-HA, which 
may occur acutely during sepsis when endotoxic shock causes end-organ damage to 
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metabolically active organs. Considering the effects of HC-HA on liver sinusoidal 
neutrophil adhesion during endotoxic shock, it may be useful to quantitatively compare 
the levels of HC-HA induced during sepsis vs. these chronic inflammatory diseases. We 
propose that there may be threshold of HC-HA needed for sequestering neutrophils in 
the liver that is more easily reached during sepsis due to the robust cytokine storm 
induction of TSG-6 secretion.   
In this thesis, we utilized two routes of LPS or bacteria administration, local IT or 
systemic IP, to model respiratory infection and sepsis (Figure 5.1A). In this acute 
inflammatory context, LPS, TNFα, and IL1β were examined as potential inflammatory 
stimuli that upregulated TSG-6 secretion. We examined both myeloid and non-
hematopoietic cellular sources (Figure 5.1B). Our findings in Chapter 2, together with 
previous results [68, 140], were used to establish the cell-specific inflammatory stimuli 
and localization (vasculature, lung interstitium, and respiratory tract) of TSG-6’s potential 
cellular sources. 
Our results in Chapter 3 suggest that HC-HA has a minimal role on outcomes of 
localized lung injury by LPS or gram negative bacterial infection including neutrophil 
recruitment into the respiratory tract. These results are consistent with previous results 
implicating CD11b/CD18 integrin as a key mediator of neutrophil adhesion, crawling, and 
emigration during gram negative lung infection [103, 198] and suggest a HC-HA/CD44 
independent regulation of neutrophil trafficking in the lung microvasculature (Figure 
5.2A). Similar to localized lung injury, interaction between CD11b/CD18 integrin and 
ICAM-1 is the key mediator of neutrophil adhesion, crawling, and emigration during 
localized liver injury (topically applied N-formyl peptide to liver surface [109]) (Figure 
5.2B). In contrast, interaction between HC-HA and CD44, not CD11b/CD18 and ICAM-1, 
regulate liver sinusoidal sequestration of neutrophils during systemic LPS and E. coli 
exposure, which is characterized by lack of emigration into liver tissue [109, 133, 134] 
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(Figure 5.2C). These findings reveal the complex role of adhesion molecules in careful 
regulation of neutrophil trafficking and localization to the site of infection and avoidance 
of off-target sites, where neutrophils would not only confer no bacterial defense, but also 
cause unnecessary tissue injury.   
The implications of the neutrophil adhesion and trapping in the liver for the 
outcomes of sepsis and endotoxic shock are not clearly defined. We have provided four 
potential mechanisms by which retaining the neutrophils in the liver sinusoids may be 
beneficial during endotoxic shock and sepsis (Figure 5.3). Since neutrophils are 
important effectors of the vascular inflammation during sepsis [199], their sequestration 
in the liver may potentially minimize systemic vascular dysfunction and life-threatening 
shock (Figure 5.3A). During systemic inflammation, the liver sinusoids can reprogram 
neutrophils by secreting anti-inflammatory IL-10 cytokine that downregulates neutrophil 
CD11b/CD18 expression and emigration (Figure 5.3B) [109]. Retaining neutrophils in 
the liver sinusoids instead of depletion by extravasation is likely ideal for successfully 
clearing bacteremia. While adherent neutrophils in the liver sinusoids during systemic 
LPS or E. coli exposure are relatively static and not crawling [109], in contrast to the lung 
microvasculature [103], they may be extruding neutrophil extracellular traps to ensnare 
and kill bacteria (Figure 5.3C) [137, 184]. Because neutrophils have a relatively short 
half-life, circulating neutrophils that are damaged or apoptotic need to be cleared. 
Kupffer cells are resident macrophages residing in the liver sinusoids that may play an 
important role in clearing neutrophils, which can minimize unnecessary neutrophil-
mediated vascular or tissue damage [110, 111] (Figure 5.3D). Investigating these 
potential mechanisms in the context of experimental sepsis is highlighted in Chapter 5.2 
Future directions.  
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Figure 5.1. Sources of TSG-6 during respiratory infection and sepsis 
A. Schematic of the two routes of bacterial or LPS exposure used to model respiratory 
infection and sepsis. Respiratory infection was induced by IT instillation of LPS or PA. 
Endotoxic shock was induced by systemic IP LPS exposure. Both routes of injury lead to 
ALI and are characterized by impaired alveolar barrier function, neutrophil recruitment, 
and vascular leak into the alveoli and lung interstitium that impair breathing (gas 
exchange). B. Cellular sources of TSG-6 during inflammation can be divided into 
myeloid and non-hematopoietic. Stimuli presented in larger font were found to more 
effectively stimulate TSG-6 secretion. LPS is the most potent stimulus in myeloid-derived 
cells. In contrast, TNFα and IL1β are the most potent inflammatory stimuli in non-
hematopoietic cells. In the lung, TSG-6 can be secreted by various cell types in both the 
respiratory tract (airway and alveolus) and interstitial compartments, which then 
facilitates HC-HA formation. During inflammation, circulating myeloid cells (neutrophil 
and monocytes) can transmigrate into the lung interstitium and alveoli. In the 
vasculature, endothelial cells and myeloid cells can contribute to TSG-6 secretion.    
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Figure 5.2. Schematic of PMN trafficking during localized vs. systemic infection 
Interactions between CD11b/CD18 integrin and ICAM-1, but not HC-HA and CD44, play 
an important role in neutrophil adhesion, crawling, and extravascular transmigration 
during localized lung (A) and liver injury (B). In contrast, interactions between HC-HA 
and CD44 play a central role in the integrin-independent neutrophil adhesion in the liver 
sinusoids during systemic LPS and E. coli exposure (C). 
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Figure 5.3. Potential mechanisms of HC-HA’s protective effects during 
sepsis/shock 
Systemic exposure to LPS or E. coli induces HC-HA/CD44-dependent PMN 
sequestration in the liver sinusoids [109, 133, 134] and is associated with improved 
survival during endotoxic shock. Proposed mechanisms by which sequestered PMN can 
act protectively during sepsis and endotoxic shock (A-D).  
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5.2 Future directions 
While we only found modest protective effects of TSG-6 in our IT LPS and PA 
respiratory infection models, this may have been due to the rapid clearance of lung 
parenchymal HC-HA in our murine model system. We performed these experiments in 
WT control littermates of our TSG-6 KO mice (BALB/c background), which exhibit less 
robust neutrophilic response to LPS and PA than C57BL/6 mice. This can be 
appreciated in the 12-day time course that was used for the RNA-seq data of AM 
isolated from C57BL/6 mice exposed to same dose of LPS (Chapter 2). Consequently, in 
response to either LPS or non-lethal PA dose, inflammation resolved very rapidly in 
BALB/c, which we assessed over a shorter 6-day time course (Chapter 3). We predict 
that TSG-6 KO mice backcrossed to C57BL/6 background would exhibit a more robust 
and persistent lung parenchymal HC-HA induction, which may provide more time for HC-
HA to exert its effects on injury and recovery outcomes. On a similar note, the prolonged 
14-day time-course of resolving viral lung infection and resolution presents a valuable 
opportunity for investigating the effects of more persistent lung parenchymal HC-HA on 
ALI outcomes.  
Besides the effect of strain background on the magnitude of response to LPS, 
there may be strain differences in HA clearance that would affect the extent of HC-HA 
accumulation and persistence. In the context of endotoxic shock, where HC-HA has 
been implicated in liver neutrophil adhesion and promoting survival, testing the effects of 
TSG-6 on different background, may also be extremely fruitful. Regarding which strain 
background to select, it is important to note that the HC-HA dependent neutrophil 
adhesion results were obtained using IαI mice on a C57BL/6 background [134]. We 
would predict that TSG-6 KO mice backcrossed to C57BL/6 background would show 
greater magnitude of survival differences in response to endotoxic shock than what we 
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observed (Chapter 4) due to potential differences in HC-HA accumulation and 
persistence.  
Neutrophils have complex roles during sepsis [200]. While they are crucial for 
eliminating bacterial infection, their exact role in contributing to vascular dysfunction and 
end-organ damage during sepsis remains poorly defined. But there is increasing 
evidence that neutrophils may have both protective and harmful effects in this context 
[167]. With the advances in intravital microscopy, more work is needed to understand 
the careful regulation of neutrophil trafficking and localization during sepsis. Our work 
highlights the need for more studies on the effect of HC-HA on neutrophil trafficking in 
the context of endotoxic shock and sepsis, which have thus far been completed only in 
the liver sinusoids with IαI KO mice. Completing these studies using TSG-6 KO mice 
would be important to rule out any HC-HA independent effects of IαI, which is an 
abundant serum protein that not only has two HC domains, but also features a protease 
inhibitor whose physiological role has been assumed to be minimal. Nonetheless, the 
evidence that the HC-HA/CD44 axis regulates neutrophil adhesion in the liver sinusoids 
is very strong due to the additional use of hyaluronidase and anti-CD44 antibody 
experiments to specifically confirm HA’s role [133].      
Thus far, all sepsis studies with TSG-6 KO mice and IαI KO mice have been 
performed using systemic LPS administration with either IV LPS [133, 134] or IP LPS 
induced endotoxic shock [135, 136]. Therefore, it remains unclear what are the effects of 
HC-HA formation during septic bacteremia, which is most commonly modeled in mouse 
using cecal ligation and puncture. As discussed (Chapter 5.1 Summary), the HC-HA-
dependent sequestration of neutrophils in the liver sinusoids may regulate systemic 
neutrophil numbers and serve to trap and eliminate circulating bacteria. Therefore, cecal 
ligation and puncture or systemic injections of defined gram negative bacteria in TSG-6 
and IαI KO mice are sorely needed to define the role of HC-HA during bacteremia.   
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While the recent discovery that HC-HA is required for initiating midgut rotation 
has raised questions regarding the embryonic fitness of TSG-6 KO mice and IαI KO 
mice [80], we and others have noted no baseline viability or gross deficits with TSG-6 
and IaI KO mice. Our findings of minimal differences in respiratory ALI outcomes 
between TSG-6 KO and control (Chapter 3) further supports the absence of any deficits. 
However, these findings cannot definitively rule out any physiological impairments 
resulting from midgut malrotation during severe injury and stress such as during 
endotoxic shock or sepsis. Therefore, intestinal inflammation should be assessed in 
future investigations with TSG-6 and IαI KO mice to control for potential differences 
arising from midgut malrotation.  
For our TSG-6 KO endotoxic shock studies, while the bone marrow was not 
investigated, this compartment is high priority for future studies due to its potential 
effects on outcomes of sepsis and endotoxic shock and the potential role of TSG-6 and 
HC-HA in the bone marrow during severe systemic inflammation. Immune dysfunction 
and neutropenia are frequent in the patient populations (infant and elderly) most 
vulnerable to sepsis-related mortality [112, 113]. Experimental models of sepsis in mice 
are characterized by myelosuppression and functional deficits in hematopoietic stem and 
progenitor cells that may be applicable to humans [114, 115].  A recent report 
highlighted the role of HA/CD44 interactions during conditions of bone marrow stress by 
demonstrating that HA/CD44 promoted hematopoietic progenitor cell proliferation 
following irradiation and engraftment [117]. Our lab has previously shown that 
exogenous TSG-6 supplementation can improve hematopoietic cell cycling and 
functionality (clonogenic capacity) and LSK (bone marrow population enriched in 
hematopoietic stem and progenitor cells) counts following cigarette smoke-induced 
myelosuppression [118]. Other labs have shown that TSG-6 can regulate bone marrow 
stromal cell differentiation [119-121]. These findings underscore the need to characterize 
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the bone marrow following endotoxic shock and sepsis in both TSG-6 and IαI KO mice to 
clearly define whether TSG-6, HC-HA, or both are acting protectively in the bone 
marrow.    
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